SE459807B - 10-ARYL-1, 8-DIHYDROXY ANTRONES, PROCEDURES FOR PREPARING THEREOF AND PHARMACEUTICAL OR COSMETIC COMPOSITIONS - Google Patents
10-ARYL-1, 8-DIHYDROXY ANTRONES, PROCEDURES FOR PREPARING THEREOF AND PHARMACEUTICAL OR COSMETIC COMPOSITIONSInfo
- Publication number
- SE459807B SE459807B SE8502910A SE8502910A SE459807B SE 459807 B SE459807 B SE 459807B SE 8502910 A SE8502910 A SE 8502910A SE 8502910 A SE8502910 A SE 8502910A SE 459807 B SE459807 B SE 459807B
- Authority
- SE
- Sweden
- Prior art keywords
- group
- hydrogen atom
- dihydroxy
- phenyl
- alkyl group
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 37
- 238000000034 method Methods 0.000 title claims description 18
- 239000002537 cosmetic Substances 0.000 title claims description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 44
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 44
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 32
- 125000000217 alkyl group Chemical group 0.000 claims description 31
- QBPFLULOKWLNNW-UHFFFAOYSA-N chrysazin Chemical compound O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O QBPFLULOKWLNNW-UHFFFAOYSA-N 0.000 claims description 25
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 24
- -1 1,8-dihydroxy- 10- (2'-methoxy-phenyl) -anthrone 1,8-dihydroxy-10- (2-thienyl) -anthrone 1,8-dihydroxy-10- (2-thiazolyl) -anthrone Chemical compound 0.000 claims description 23
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 22
- 125000003545 alkoxy group Chemical group 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 16
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 13
- 229960001577 dantron Drugs 0.000 claims description 13
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims description 11
- 125000005843 halogen group Chemical group 0.000 claims description 11
- 229910021626 Tin(II) chloride Inorganic materials 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 10
- 235000011150 stannous chloride Nutrition 0.000 claims description 10
- 150000005691 triesters Chemical class 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 150000005690 diesters Chemical class 0.000 claims description 7
- 150000002148 esters Chemical class 0.000 claims description 7
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 claims description 6
- 239000001119 stannous chloride Substances 0.000 claims description 6
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 5
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 5
- 150000002825 nitriles Chemical group 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 208000001840 Dandruff Diseases 0.000 claims description 4
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims description 4
- 230000020477 pH reduction Effects 0.000 claims description 4
- 201000004384 Alopecia Diseases 0.000 claims description 3
- 239000013543 active substance Substances 0.000 claims description 3
- 208000024963 hair loss Diseases 0.000 claims description 3
- 230000003676 hair loss Effects 0.000 claims description 3
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 3
- DYSZXCJPBJXHNR-UHFFFAOYSA-N (8,9-diacetyloxy-10-thiophen-2-ylanthracen-1-yl) acetate Chemical compound C12=CC=CC(OC(C)=O)=C2C(OC(C)=O)=C2C(OC(=O)C)=CC=CC2=C1C1=CC=CS1 DYSZXCJPBJXHNR-UHFFFAOYSA-N 0.000 claims description 2
- YHTSSKFQQBCONG-UHFFFAOYSA-N 1,8-dihydroxy-10-(4-methoxyphenyl)-10h-anthracen-9-one Chemical compound C1=CC(OC)=CC=C1C1C2=CC=CC(O)=C2C(=O)C2=C(O)C=CC=C21 YHTSSKFQQBCONG-UHFFFAOYSA-N 0.000 claims description 2
- 206010039792 Seborrhoea Diseases 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims 1
- 206010042496 Sunburn Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- WYFNKQYPMFPFEN-UHFFFAOYSA-N [8,9-di(propanoyloxy)-10-thiophen-2-ylanthracen-1-yl] propanoate Chemical compound C12=CC=CC(OC(=O)CC)=C2C(OC(=O)CC)=C2C(OC(=O)CC)=CC=CC2=C1C1=CC=CS1 WYFNKQYPMFPFEN-UHFFFAOYSA-N 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 239000000047 product Substances 0.000 description 43
- 239000000243 solution Substances 0.000 description 42
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 22
- 239000011541 reaction mixture Substances 0.000 description 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 16
- 238000000921 elemental analysis Methods 0.000 description 16
- 239000013078 crystal Substances 0.000 description 15
- 238000001228 spectrum Methods 0.000 description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- 229960000583 acetic acid Drugs 0.000 description 14
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 13
- 230000008018 melting Effects 0.000 description 13
- 238000002844 melting Methods 0.000 description 13
- 239000000725 suspension Substances 0.000 description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 11
- 239000012298 atmosphere Substances 0.000 description 11
- 238000001819 mass spectrum Methods 0.000 description 11
- 239000012362 glacial acetic acid Substances 0.000 description 9
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 9
- 235000019341 magnesium sulphate Nutrition 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 229910052786 argon Inorganic materials 0.000 description 8
- 239000000741 silica gel Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 238000004587 chromatography analysis Methods 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 239000012429 reaction media Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- LHSYEMPUQITWPP-UHFFFAOYSA-N 1,8-dihydroxy-10-(3-methoxyphenyl)-10h-anthracen-9-one Chemical compound COC1=CC=CC(C2C3=CC=CC(O)=C3C(=O)C3=C(O)C=CC=C32)=C1 LHSYEMPUQITWPP-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 229940099259 vaseline Drugs 0.000 description 4
- KTDJJFMEWQUHCB-UHFFFAOYSA-N 1,8-dihydroxy-10-(2-methoxyphenyl)-10h-anthracen-9-one Chemical compound COC1=CC=CC=C1C1C2=CC=CC(O)=C2C(=O)C2=C(O)C=CC=C21 KTDJJFMEWQUHCB-UHFFFAOYSA-N 0.000 description 3
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 3
- DPZNOMCNRMUKPS-UHFFFAOYSA-N 1,3-Dimethoxybenzene Chemical compound COC1=CC=CC(OC)=C1 DPZNOMCNRMUKPS-UHFFFAOYSA-N 0.000 description 2
- LDVDPDKUOPOPJA-UHFFFAOYSA-N 1,8,10-trihydroxy-10-(4-methoxyphenyl)anthracen-9-one Chemical compound C1=CC(OC)=CC=C1C1(O)C2=CC=CC(O)=C2C(=O)C2=C(O)C=CC=C21 LDVDPDKUOPOPJA-UHFFFAOYSA-N 0.000 description 2
- QYIPTEPRZGPMBI-UHFFFAOYSA-N 1,8-dihydroxy-10-(3-hydroxyphenyl)-10h-anthracen-9-one Chemical compound OC1=CC=CC(C2C3=CC=CC(O)=C3C(=O)C3=C(O)C=CC=C32)=C1 QYIPTEPRZGPMBI-UHFFFAOYSA-N 0.000 description 2
- LSXPZLOKQYXPNN-UHFFFAOYSA-N 1,8-dihydroxy-10-thiophen-2-yl-10h-anthracen-9-one Chemical compound C12=CC=CC(O)=C2C(=O)C=2C(O)=CC=CC=2C1C1=CC=CS1 LSXPZLOKQYXPNN-UHFFFAOYSA-N 0.000 description 2
- PLDWAJLZAAHOGG-UHFFFAOYSA-N 1-bromo-3-methoxybenzene Chemical compound COC1=CC=CC(Br)=C1 PLDWAJLZAAHOGG-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- GNRURUVTPFVSCI-UHFFFAOYSA-N 2-hydroxy-2h-anthracen-1-one Chemical compound C1=CC=C2C=C(C(C(O)C=C3)=O)C3=CC2=C1 GNRURUVTPFVSCI-UHFFFAOYSA-N 0.000 description 2
- FIHZWZBEAXASKA-UHFFFAOYSA-N Anthron Natural products COc1cc2Cc3cc(C)cc(O)c3C(=O)c2c(O)c1C=CC(C)C FIHZWZBEAXASKA-UHFFFAOYSA-N 0.000 description 2
- ZCTQGTTXIYCGGC-UHFFFAOYSA-N Benzyl salicylate Chemical compound OC1=CC=CC=C1C(=O)OCC1=CC=CC=C1 ZCTQGTTXIYCGGC-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- WDHBAQITVJWMOM-UHFFFAOYSA-N [8,9-diacetyloxy-10-(3-methoxyphenyl)anthracen-1-yl] acetate Chemical compound COC1=CC=CC(C=2C3=CC=CC(OC(C)=O)=C3C(OC(C)=O)=C3C(OC(C)=O)=CC=CC3=2)=C1 WDHBAQITVJWMOM-UHFFFAOYSA-N 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 2
- 150000004056 anthraquinones Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 150000002681 magnesium compounds Chemical class 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000000052 vinegar Substances 0.000 description 2
- 235000021419 vinegar Nutrition 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- GPBGABQDMYVXTM-UHFFFAOYSA-N 1,8,10-trihydroxy-10-(2-methoxyphenyl)anthracen-9-one Chemical compound COC1=CC=CC=C1C1(O)C2=CC=CC(O)=C2C(=O)C2=C(O)C=CC=C21 GPBGABQDMYVXTM-UHFFFAOYSA-N 0.000 description 1
- GNMAACAKIIEHFV-UHFFFAOYSA-N 1,8,10-trihydroxy-10-(3-methoxyphenyl)anthracen-9-one Chemical compound COC1=CC=CC(C2(O)C3=CC=CC(O)=C3C(=O)C3=C(O)C=CC=C32)=C1 GNMAACAKIIEHFV-UHFFFAOYSA-N 0.000 description 1
- VXISSPQWQDAILF-UHFFFAOYSA-N 1,8,10-trihydroxy-10-[3-(trifluoromethyl)phenyl]anthracen-9-one Chemical compound OC1=CC=CC2=C1C(=O)C1=C(O)C=CC=C1C2(O)C1=CC=CC(C(F)(F)F)=C1 VXISSPQWQDAILF-UHFFFAOYSA-N 0.000 description 1
- HWXLLNAYIZZBDS-UHFFFAOYSA-N 1,8-dihydroxy-10-(1,3-thiazol-2-yl)-10h-anthracen-9-one Chemical compound C12=CC=CC(O)=C2C(=O)C=2C(O)=CC=CC=2C1C1=NC=CS1 HWXLLNAYIZZBDS-UHFFFAOYSA-N 0.000 description 1
- HTDQSWDEWGSAMN-UHFFFAOYSA-N 1-bromo-2-methoxybenzene Chemical compound COC1=CC=CC=C1Br HTDQSWDEWGSAMN-UHFFFAOYSA-N 0.000 description 1
- WVXWGPGAWUOYOV-UHFFFAOYSA-N 10-(2,4-dimethoxyphenyl)-1,8,10-trihydroxyanthracen-9-one Chemical compound COC1=CC(OC)=CC=C1C1(O)C2=CC=CC(O)=C2C(=O)C2=C(O)C=CC=C21 WVXWGPGAWUOYOV-UHFFFAOYSA-N 0.000 description 1
- LWJNWXYSLBGWDU-UHFFFAOYSA-N 2,2-dimethyl-n-phenylpropanamide Chemical compound CC(C)(C)C(=O)NC1=CC=CC=C1 LWJNWXYSLBGWDU-UHFFFAOYSA-N 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- RXNZFHIEDZEUQM-UHFFFAOYSA-N 2-bromo-1,3-thiazole Chemical compound BrC1=NC=CS1 RXNZFHIEDZEUQM-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- QJPJQTDYNZXKQF-UHFFFAOYSA-N 4-bromoanisole Chemical compound COC1=CC=C(Br)C=C1 QJPJQTDYNZXKQF-UHFFFAOYSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 1
- RZVHIXYEVGDQDX-UHFFFAOYSA-N 9,10-anthraquinone Chemical group C1=CC=C2C(=O)C3=CC=CC=C3C(=O)C2=C1 RZVHIXYEVGDQDX-UHFFFAOYSA-N 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- RGCKGOZRHPZPFP-UHFFFAOYSA-N Alizarin Natural products C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- KHZIHFPFSXFUCV-UHFFFAOYSA-N [10-(3-methoxyphenyl)-8,9-di(propanoyloxy)anthracen-1-yl] propanoate Chemical compound C12=CC=CC(OC(=O)CC)=C2C(OC(=O)CC)=C2C(OC(=O)CC)=CC=CC2=C1C1=CC=CC(OC)=C1 KHZIHFPFSXFUCV-UHFFFAOYSA-N 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 230000003255 anti-acne Effects 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- GTZOYNFRVVHLDZ-UHFFFAOYSA-N dodecane-1,1-diol Chemical compound CCCCCCCCCCCC(O)O GTZOYNFRVVHLDZ-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- RBBOWEDMXHTEPA-UHFFFAOYSA-N hexane;toluene Chemical compound CCCCCC.CC1=CC=CC=C1 RBBOWEDMXHTEPA-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 150000002900 organolithium compounds Chemical class 0.000 description 1
- 125000002734 organomagnesium group Chemical group 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- IUTCEZPPWBHGIX-UHFFFAOYSA-N tin(2+) Chemical compound [Sn+2] IUTCEZPPWBHGIX-UHFFFAOYSA-N 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/703—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
- C07C49/723—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups polycyclic
- C07C49/727—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups polycyclic a keto group being part of a condensed ring system
- C07C49/737—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups polycyclic a keto group being part of a condensed ring system having three rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Description
10 15 20 30 35 459 807 vari R1, R2, R3, R4 och R5, lika eller olika, betecknar en väte- atom, en halogenatom, gruppen -CF3, en hydroxylfunktion, en lägre alkylgrupp, en lägre cykloalkylgrupp, en lägre hydr- oxialkylgruPP. en lägre alkoxigrupp, en nitrilfunktion, QIUPP en I -so N/r ,-mn)-con/I' -mH)-N/ I 2 \r'l 237- \rn' 211 \ru I ' O----- -N-CO R' _ CH -CO ' - än 1 ( 2)n ZR eller (CH2)¿§š N I' 0Ch I", lika eller olika, betecknar en väteatom eller en lägre alkylgrupp, n är 0 eller ett heltal fr.o.m. 1 t.o.m. 3, och R' och R" betecknar en väteatom, en lägre alkylgrupp, rak eller grenad, varvid alkyl- och arylgrupperna ovan eventuellt kan vara substituerade, och varvid minst en av grupperna R 1 till R5 är skild från en väteatom, Re ,/' (ii) \\N Ra (111) S R6 betecknar en av de betydelser, som givits för grupperna R till R5 och 1 S /Q N och mono-, di- och tri-estrarna därav med formeln II 10 15 20 25 30 35 s 459 807 (II) vari Ar har samma betydelse som givits här ovan för föreningarna med formeln (I), p är 0 eller 1. 10 15 20 30 35 459 807 wherein R 1, R 2, R 3, R 4 and R 5, the same or different, denote a hydrogen atom, a halogen atom, the group -CF3, a hydroxyl function, a lower alkyl group, a lower cycloalkyl group, a lower hydrogen oxyalkyl group. a lower alkoxy group, a nitrile function, QIUPP one IN -so N / r, -mn) -con / I '-mH) -N / I 2 \ r'l 237- \ rn '211 \ ru I' O----- -N-CO R '_ CH -CO' - than 1 (2) n ZR or (CH2) ¿§š N I'CCh I ", the same or different, denotes a hydrogen atom or a lower alkyl group, n is 0 or an integer from 1 p.m. 3, and R 'and R "represent a hydrogen atom, a lower alkyl group, straight or branched, the alkyl and aryl groups above optionally may be substituted, and wherein at least one of the groups R 1 to R5 is separated from a hydrogen atom, Re, / ' (ii) \\ N Ra (111) S R6 represents one of the meanings given to the groups R6 to R5 and 1 S / Q N and the mono-, di- and tri-esters thereof of formula II 10 15 20 25 30 35 s 459 807 (II) wherein Ar has the same meaning as given above for the associations of formula (I), p is 0 or 1.
När p = 0, betecknar R8 en väteatom eller -COR och R be- 10 9 tecknar -C0R10 och p' är 1, när p = 1, betecknar R7: 1) en väteatom, R8 betecknar en väteatom eller gruppen -COR1O, R9 betecknar gruppen -COR10 och p' är 0, 2) eller gruppen -COR1o, R8 och R9 betecknar gruppen -COR10 och p' är 0, R10 betecknar en rak eller grenad alkylgrupp med från 1 till 10 kolatomer, en cykloalkylgrupp, en 2-pyridylgrupp, en 2-tie- nylgrupp eller en fenylgrupp eventuellt substituerad med en lägre alkylgrupp, en lägre alkoxigrupp, en halogenatom, en nit- rofunktion, en grupp -CF3 eller med en hydroxylfunktion och blandningar av dessa estrar.When p = 0, R 8 represents a hydrogen atom or -COR and R 10 9 denotes -COR10 and p 'is 1, when p = 1, R 7 denotes: 1) a hydrogen atom, R 8 represents a hydrogen atom or the group -COR10, R9 represents the group -COR10 and p 'is 0, 2) or the group -COR 10, R 8 and R 9 represents the group -COR10 and p 'are 0, R10 represents a straight or branched alkyl group having from 1 to 10 carbon atoms, a cycloalkyl group, a 2-pyridyl group, a 2-thio- nyl group or a phenyl group optionally substituted by a lower alkyl group, a lower alkoxy group, a halogen atom, a nitrous oxide ro function, a group -CF3 or with a hydroxyl function and mixtures of these esters.
När grupperna R1 till R5 betecknar en halogenatom, är denna företrädesvis en fluor- eller kloratom.When the groups R1 to R5 represent a halogen atom, this is preferably a fluorine or chlorine atom.
Med en lägre alkylgrupp förstås enligt uppfinningen en grupp med från 1 till 6 kolatomer, företrädesvis en metyl-, etyl-, propyl-, isopropyl-, butyl-, isobutyl-, t.-butyl-, pentyl-, isopentyl- eller hexylgrupp. 10 15 20 25 30 35 459 807 a 4 Med lägre alkoxigrupp förstås en grupp med från 1 till 4 kol- atomer, i synnerhet en metoxi- , etoxi-, propoxi- eller iso- propoxigrupp.By a lower alkyl group is meant according to the invention a group having from 1 to 6 carbon atoms, preferably a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl or hexyl group. 10 15 20 25 30 35 459 807 a 4 By lower alkoxy group is meant a group having from 1 to 4 carbon atoms, in particular a methoxy- , ethoxy, propoxy or iso- propoxy group.
Med en lägre cykloalkylgrupp förstås en cyklopropyl-, cyklo- butyl-, cyklopentyl- eller cyklohexylgrupp.By a lower cycloalkyl group is meant a cyclopropyl, cyclo- butyl, cyclopentyl or cyclohexyl group.
Med lägre hydroxialkylgrupp förstås en grupp med från 1 till' 3 kolatomer och isynnerhet en hydroximetyl- , 2-hydroxí-etyl- eller 2,3-dihydroxi-propylgrupp.By lower hydroxyalkyl group is meant a group having from 1 to 3 carbon atoms and in particular a hydroxymethyl- , 2-hydroxy-ethyl- or 2,3-dihydroxypropyl group.
När i föreningarna med formeln (I) gruppen Ar betecknar en aromatisk rest med formeln: R5 R4 Rs // RI Rz är de föredragna föreningarna de i vilka: 1) R1 (eller RS) betecknar en lägre alkoxigrupp eller en grupp med formeln: -N - COR' I RI! R' betecknar en rak eller grenad alkylgrupp med från 1 till 5 kolatomer och R" betecknar en väteatom, R3 betecknar en väte- atom eller en lägre alkoxigrupp och R2, R4 och RS (eller R1) betecknar en väteatom. 2) R2 (eller R4) betecknar en grupp -CF3, en lägre alkoxi- grupp eller en hydroxylfunktion och R1, R3, R4 (eller R2) och RS betecknar en väteatom, och 3) R3 betecknar en lägre alkoxigrupp och R1, R 2, R4 och R5 betecknar en väteatom. 10 15 20 25 30 35 459 807 Enligt en föredragen utföringsform betecknar gruppen R6 en väteatom.When in the compounds of formula (I) the group Ar represents a aromatic residue of the formula: R5 R4 Rs // RI Rz the preferred compounds are those in which: 1) R 1 (or R 5) represents a lower alkoxy group or group with the formula: -N - COR ' IN RI! R 'represents a straight or branched alkyl group having from 1 to 5 carbon atoms and R "represents a hydrogen atom, R3 represents a hydrogen atom atom or a lower alkoxy group and R 2, R 4 and R 5 (or R 1) denotes a hydrogen atom. 2) R 2 (or R 4) represents a group -CF 3, a lower alkoxy- group or a hydroxyl function and R 1, R 3, R 4 (or R 2) and RS denotes a hydrogen atom, and 3) R 3 represents a lower alkoxy group and R 1, R 2, R4 and R5 denotes a hydrogen atom. 10 15 20 25 30 35 459 807 According to a preferred embodiment, the group R 6 denotes a hydrogen atom.
Bland föreningarna med formeln (I) kan man isynnerhet nämna följande: 1,8-dihydroxi-10-(N-2",2"-dimetylpropanoyl)-2'-amino-fenyl-antron 1,8-dihydroxi-10-(2',4'-dimetoxi-fenyl)-antron 1,8-dihydroxi-10-(4'-metoxi-fenyl)-antron 1,8-dihydroxi-10(3'-trifluorometyl-fenyl)-antron 1,8-dihydroxi-10-(3'-metoxi-fenyl)-antron 1,8-dihydroxi-10%3'-hydroxi-fenyl)-antron 1,8-dihydroxi-10-(2'-metoxi-fenyl)-antron 1,8-dihydroxi-10-(2-tienyl)-antron 1,8-dihydroxi-1042-tiazolyl)-antron.Among the compounds of formula (I), mention may be made in particular following: 1,8-Dihydroxy-10- (N-2 ", 2" -dimethylpropanoyl) -2'-amino-phenyl-anthrone 1,8-Dihydroxy-10- (2 ', 4'-dimethoxy-phenyl) -anthrone 1,8-Dihydroxy-10- (4'-methoxy-phenyl) -anthrone 1,8-Dihydroxy-10 (3'-trifluoromethyl-phenyl) -antrone 1,8-Dihydroxy-10- (3'-methoxy-phenyl) -anthrone 1,8-dihydroxy-10% 3'-hydroxy-phenyl) -anthrone 1,8-Dihydroxy-10- (2'-methoxy-phenyl) -anthrone 1,8-Dihydroxy-10- (2-thienyl) -anthrone 1,8-dihydroxy-1042-thiazolyl) -antrone.
Bland de raka eller grenade alkylgrupperna med från 1 till 10 kolatomer kan man nämna metyl-, etyl-, propyl-, isopropyl-, butyl-, isobutyl-, t.-butyl-, pentyl-, isopentyl-, heptyl-, nonyl- och decylgrupperna. l När gruppen R10 betecknar en cykloalkylgrupp är denna en cyk- lopropyl-, cyklobutyl-, cyklopentyl- eller cyklohexylgrupp.Among the straight or branched alkyl groups having from 1 to 10 carbon atoms include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, heptyl, the nonyl and decyl groups. l When the group R10 represents a cycloalkyl group, this is a cycloalkyl group. lopropyl, cyclobutyl, cyclopentyl or cyclohexyl group.
När fenylgruppen är substituerad med en alkylgrupp är denna företrädesvis en metyl-, etyl- eller t.-butylgrupp.When the phenyl group is substituted with an alkyl group it is preferably a methyl, ethyl or t-butyl group.
När fenylgruppen är substituerad med en aikoxigrupp är denna företrädesvis en metoxi- eller etoxigrupp.When the phenyl group is substituted with an alkoxy group, this is preferably a methoxy or ethoxy group.
När fenylgruppen är substituerad med en halogenatom är denna företrädesvis en klor- eller fluoratom.When the phenyl group is substituted with a halogen atom, this is preferably a chlorine or fluorine atom.
Såsom framgår av den allmänna formeln (II) här ovan kan est- rarna enligt uppfinningen föreligga i form av mono- eller di- -estrar av 10-acyl-1,8-dihydroxi-antron eller deras isomerer, nämligen mono- eller di-estrarna av 10-acyl-1,8-dihydroxi-9- -antranol eller vidare i form av triestrar av 10-acyl-1,8-di- hydroxi-9-antranol. 10 15 20 25 30 35 459 807 e Bland estrarna med formeln (II) kan man isynnerhet nämna föl- jande: 10-(3'-metoxi-fenyl)-1.8.9-triacetoxi-antracen 10-(3'-metoxi-fenyl)-1.8,9-tripropanoyloxi-antracen 10-(2-tienyl)-1.8.9-triacetoxí-antracen 10-(2-tíenyl)-1.8.9-tripropanoyloxi-antracen 10-(2-tienyl)-1.8-dipivaloyloxi-antron Föreningar med formeln (I) enligt uppfinningen erhålles i tvâ steg utgående från 1.8-díhydroxi-antrakinon enligt följande reaktíonsschema: on o on on o en I) Ar- 2) n* ° Ar ou <9 <_2_> ou o ou Ar U) Det första steget består i att omsätta en aromatisk karbanjon med 1,8-dihydroxi-antrakinonen (I) som. efter surgöring. till föreningen med formeln (II). leder Det andra steget består i att reducera mellanprodukten (2) i närvaro av metalliskt tenn eller tenn(II)k1orid. vilket leder till föreningen med formeln (I) enligt uppfinningen.As can be seen from the general formula (II) above, the compounds according to the invention are in the form of mono- or di- esters of 10-acyl-1,8-dihydroxyanthron or their isomers, namely the mono- or di-esters of 10-acyl-1,8-dihydroxy-9- -anthranol or further in the form of triesters of 10-acyl-1,8-di- hydroxy-9-anthranol. 10 15 20 25 30 35 459 807 e Among the esters of formula (II), mention may be made in particular of the following jande: 10- (3'-methoxy-phenyl) -1.8.9-triacetoxy-anthracene 10- (3'-methoxy-phenyl) -1,8,9-tripropanoyloxy-anthracene 10- (2-thienyl) -1.8.9-triacetoxy-anthracene 10- (2-thienyl) -1.8.9-tripropanoyloxy anthracene 10- (2-thienyl) -1,8-dipivaloyloxy-anthrone Compounds of formula (I) according to the invention are obtained in two steps starting from 1,8-dihydroxyanthraquinone as follows reaction scheme: on o on on o o I) Ar- 2) n * ° Ar ou <9 <_2_> ou o ou Are U) The first step is to convert an aromatic carbonate with the 1,8-dihydroxy-anthraquinone (I) as. after acidification. to the compound of formula (II). leader The second step is to reduce the intermediate (2) in presence of metallic tin or tin (II) chloride. which leads to the compound of formula (I) according to the invention.
Tillgången på den aromatiska karbanjonen kan tillhandahållas antingen utgående från en litíumorganisk förening eller en magnesiumorganisk förening. 10 15 20 25 30 35 7 459 807 De aromatiska litiumorganiska föreningarna kan erhållas med två olika metoder: Den första metoden består í att omsätta butyllitiun eller dess komplex med tetrametyletylendiamin med en aromatisk förening. vars föreliggande substituent eller substituenter aktiverar det kol på vilket man önskar utföra metallsyntesen med den senare.The supply of the aromatic carbonate can be provided either starting from an organometallic compound or a magnesium organic compound. 10 15 20 25 30 35 7 459 807 The aromatic lithium organic compounds can be obtained with two different methods: The first method consists in converting butyllithium or its complex with tetramethylethylenediamine with an aromatic compound. whose present substituent or substituents activate the carbon on which it is desired to perform the metal synthesis with it later.
Man kan isynnerhet använda metoderna som beskrives av D.W.In particular, the methods described by D.W.
SLOCUH et al. J.O.C., sid. 3653, 1976 eller av V. SNIECKUS et al. J.O.C.. 44. sid. 4803. 1979.SLOCUH et al. J.O.C., p. 3653, 1976 or by V. SNIECKUS et al. J.O.C .. 44. p. 4803. 1979.
Den andra metoden för framställning av aromatiska litiumföre- ningar består i att behandla ett halogenerat aromatiskt deri- vat, isynnerhet ett bromerat derivat med butyllitíum med de som beskrives av P. BEAK et al.. Ace. Chem. Res., 306. 1982 et H.E. PARHAH et al.. Aco. Chem. Res. 1982. metoder, sid. sid. 300, När man önskar erhålla den aromatiska karbanjonen utgående från en magnesiumförening använder man såsom i den föregående metoden ett halogenerat aromatískt derivat. som man omvandlar med de vanliga metoderna till magnesiumförening i ett vatten- fritt lösningsmedel såsom tetrahydrofuran eller eter.The second method for producing aromatic lithium compounds consists in treating a halogenated aromatic derivative water, in particular a brominated derivative of butyllithium with de as described by P. BEAK et al., Ace. Chem. Res., 306. 1982 and H.E. PARHAH et al., Aco. Chem. Res. 1982. methods, sid. sid. 300, When it is desired to obtain the aromatic carbonate outgoing from a magnesium compound is used as in the foregoing the method a halogenated aromatic derivative. which one converts with the usual methods of magnesium compound in an aqueous free solvent such as tetrahydrofuran or ether.
Det förfarande. som består i att omsätta en aromatisk litíum- förening med 1.8-dinydroxi-antrakínonen. föredrages speciellt ty i motsats till den aromatiska magnesiumföreningen leder detta förfarande till en selektiv addition på karbonylen i 10-ställning i antrakinonkârnan. vilket inte år fallet med de aromatiska magnesiumföreningarna, ty man observerar i vissa fall en addition 1 9-ställning..That procedure. consisting of the conversion of an aromatic lithium compound with the 1,8-dinydroxy anthraquinone. especially preferred for in contrast to the aromatic magnesium compound leads this process to a selective addition of the carbonyl in 10-position in the anthraquinone core. which is not the case with those the aromatic magnesium compounds, for one observes in some case an addition 1 9 position ..
Man har vidare konstaterat att genom att använda ett stort överskott av aromatisk lítiumförening på minst 4 molekvívalen- ter i förhållande till l,8-dinydroxi-antrakinonen är det inte nödvändigt. såsom i de kända förfarandena. att anlita ett 10 15 20 25 30 35 459 807 8 skydd av hydroxylfunktionen l- eller 8-ställning för att er- nålla aromatiska derivat i 10-ställning i antronkärnan.It has further been found that by using a large excess lithium aromatic compound of at least 4 molar equivalents in relation to the 1,8-dinydroxy anthraquinone is not necessary. as in the known methods. to hire one 10 15 20 25 30 35 459 807 8 protection of the hydroxyl function 1 or 8 position in order to needle aromatic derivatives in the 10-position in the anthron nucleus.
Additionsreaktionen av den aromatiska litiumföreningen på 1.8- -dihydroxi-antrakinonen utföres i allmänhet i ett vattenfritt lösningsmedel såsom etyleter eller tetranydrofuran vid en tem- peratur mellan -B0 och 0°C genom tillsats av den aromatiska litiumföreningen ' 1 eter eller tetrahydrofuran till en lösning i samma lösningsmedel av l.8-dihydroxi-antrakinonen.The addition reaction of the aromatic lithium compound on 1.8- The dihydroxy anthraquinone is generally carried out in an anhydrous solvents such as ethyl ether or tetranydrofuran at a temperature temperature between -B0 and 0 ° C by adding the aromatic lithium compound ' 1 ether or tetrahydrofuran to a solution in the same solvent of the 1,8-dihydroxy-anthraquinone.
Efter tillsatsen hâlles reaktionshlandningen under omrörning vid samma temperatur under en tid mellan 30 minuter till 2 timmar. Reaktíonens slut bestämmes genom frånvaron av l.8-dí- hydroxi-antrakinon genom tunnskiktskromatografi.After the addition, the reaction mixture is kept under stirring at the same temperature for a time between 30 minutes to 2 hours. The end of the reaction is determined by the absence of 1,8-di- hydroxyanthraquinone by thin layer chromatography.
Man fortsätter därefter surgöringen av reaktionsblandningen vid rumstemperatur, varefter man tvättar med vatten och torkar den organiska fasen över vattenfritt magnesiumsulfat.The acidification of the reaction mixture is then continued at room temperature, after which it is washed with water and dried the organic phase over anhydrous magnesium sulphate.
Efter avdrivning av lösníngsmedlet renas mellanprodukten (2) eller lO-aryl-1.8.10-trihydroxi-antronen genom omkristallisa- tion eller kromatografi på silikagel.After evaporation of the solvent, the intermediate is purified (2) or the 10-aryl-1,8,10-trihydroxy anthron by recrystallization from chromatography on silica gel.
När omsättningen utföres utgående från en aromatisk magnesium- förening liknar reaktionsbetingelserna dem. som användes ut- gående från en aromatisk litiumförening, men efter avslutad tillsats låter man återgå till rumstemperatur och fortsätter omrörningen flera timmar. eventuellt under återlopp av lös- ningsmedel. tills l.8-dihydroxi-antrakinonen försvinner vid tunnskiktskromatografi.When the reaction is carried out on the basis of an aromatic magnesium compound is similar to the reaction conditions. which was used going from an aromatic lithium compound, but after completion addition is allowed to return to room temperature and continues stirring for several hours. possibly during reflux of means. until the 1,8-dihydroxy anthraquinone disappears at thin layer chromatography.
Det andra steget vid förfarandet består i att reducera 10-aryl-1,8.10-trihydroxi-antronen (II) för att erhålla före- ningarna enligt uppfinningen med formeln (I). varvid denna re- duktionsreaktíon utföres i ättikssur miljö i närvaro av tenn(II)klorid eller metalliskt tenn och koncentrerad saltsyra. 10 15 20 25 30 35 9 459 807 Omsättningen utföres i allmänhet vid rumstemperatur under en tid mellan 1/2 och 5 timmar, varvid reaktionens slutpunkt be- stämmes genom frånvaron av utgångsprodukten med tunnskikts- kromatografi. F* om omsättningen inte är fullständig kan reaktionsblandningen hållas på vattenbad.The second step in the process is to reduce 10-aryl-1,8.10-trihydroxy-anthrone (II) to obtain the compounds of the invention of formula (I). whereby this re- production reaction is carried out in an acetic acid environment in the presence of stannous chloride or metallic tin and concentrated hydrochloric acid. 10 15 20 25 30 35 9 459 807 The reaction is generally carried out at room temperature below one time between 1/2 and 5 hours, the end point of the reaction being due to the absence of the starting product with the thin-film chromatography. F * if the reaction is not complete, the reaction mixture may held in water baths.
Efter återgång till rumstemperatur hâlles reaktionsblandningen i vatten, vilket orsakar utfällning av den önskade produkten, som sedan renas genom omkristallisation i ett lämpligt lös- ningsmedel.After returning to room temperature, the reaction mixture is kept in water, causing precipitation of the desired product, which is then purified by recrystallization into a suitable solution. means.
Estrarna med formeln (II) erhålles genom omsättning av en lämplig syraanhydrid med en 10-aryl-l.8-dihydroxi-antrakinon med formeln (I) i närvaro av några droppar pyridin och genom att eventuellt bringa reaktionsblandningen till en temperatur mellan 50 och l30°C eller genom att använda en syraklorid i närvaro av pyridin i stökiometrisk mängd i ett aromatiskt lös- ningsmedel såsom toluen.The esters of formula (II) are obtained by reacting a suitable acid anhydride with a 10-aryl-1,8-dihydroxy-anthraquinone with formula (I) in the presence of a few drops of pyridine and by to optionally bring the reaction mixture to a temperature between 50 and 130 ° C or by using an acid chloride in presence of pyridine in stoichiometric amount in an aromatic solution agents such as toluene.
Framställningen av mono-, di- eller tri-estrarna är en funk- tion av molproportionerna av den omsatta syraanhydriden eller syrakloriden och reaktionstiden.The preparation of the mono-, di- or tri-esters is a functional the molar proportions of the acid anhydride reacted or the acid chloride and the reaction time.
Uppfinningen avser även farmaceutiska och kosmetiska komposi- tioner kännetecknade av att de såsom aktiv ingrediens innehål- ler minst en förening med formeln I eller II.The invention also relates to pharmaceutical and cosmetic compositions. characterized in that they contain as active ingredient at least one compound of formula I or II.
I dessa kompositioner varierar koncentrationen av aktiv ingre- diens 1 allmänhet från 0.005 till 170 vikt-2 som funktion av administreringssättet.In these compositions, the concentration of active ingredient varies. dies 1 generally from 0.005 to 170 wt-2 as a function of method of administration.
Dessa kompositioner kan dessutom innehålla inerta eller farma- kodynamiskt aktiva tillsatser t.ex. bindemedel. fyllmedel. ut- drygningsmedel, förtjockningsmedel, konserveringsmedel etc. 10 15 20 25 30 35 459 807 1° Kompositionerna administrerade oralt kan även innehålla smak- medel. xompositionerna administrerade topiskt kan föreligga i form av pomaäor. salvor. krämer. geler. tinkturer. lösningar. lotio- ner. sprayer. suspensioner, nikroniserade pulver eller shampo- neringsmedel.These compositions may additionally contain inert or pharmaceutical compositions. codynamically active additives e.g. binder. fillers. out- additives, thickeners, preservatives, etc. 10 15 20 25 30 35 459 807 1 ° The compositions administered orally may also contain flavoring agents. average. the compositions administered topically may be present in the shape of pomaäor. salvor. creams. gels. tinctures. solutions. lotio- down. sprayer. suspensions, micronized powders or shampoos nutrients.
Enligt denna utföríngsforn anbringar man på de zoner av huden. som skall behandlas. í en eller två adninistreringar från 1 till S g av en komposition innehållande från 0.01 till 5 g av den aktiva substansen per 100 g komposition.According to this embodiment, apply man on the zones of the skin. to be treated. í one or two administrations from 1 to S g of a composition containing from 0.01 to 5 g of the active substance per 100 g of composition.
De kompositioner. som administreras enteralt eller parenteralt kan föreligga i form av tabletter. granulat. gelatinkapslar. kapslar. sírupar. drickbara suspensioner. påse eller vidare í pensioner. svâljbara pulver i form av injicerbara lösningar eller sus- För den enterala eller parenterala administreringen ger man i allmänhet från 0.05 till 5 g av den aktiva substansen per dag till den vuxna i en eller tvâ omgångar.The compositions. administered enterally or parenterally may be in the form of tablets. granules. gelatin capsules. capsules. sírupar. drinkable suspensions. bag or further í pensions. swallowable powder i in the form of injectable solutions or For enteral or parenteral administration, give in generally from 0.05 to 5 g of the active substance per day to the adult in one or two rounds.
De utförda försöken har kunnat visa att föreningarna enligt uppfinningen har en bra aktivitet när de inkorporeras i olika farmaceutiska eller kosmetiska vehiklar.The experiments performed have been able to show that the associations according to the invention has a good activity when incorporated into various pharmaceutical or cosmetic vehicles.
Nedan återges såsom illustration och utan någon som helst be- gränsande karaktâr flera exempel på framställning av förening- arna enligt uppfinningen.Below is shown by way of illustration and without any restrictive nature several examples of the production of according to the invention.
Exempel 1 Framstâllning av 1.8-dihvdroxi-10-ÉRN-2",2"-dimetyl-pro- panovl)-2'-amino-fenyl]-antron. a) Till 18 g N-pivaloylanilin i 100 cm3 tetrahydrofuran (THF) vattenfri sätter man vid 0°C under inert atmosfär 100 cm3 n-butyl-iitium (2,5 u). 10 15 20 25 30 35 n 459 807 Efter tillsats lämnar man reaktionsblandningen under 24 timmar vid rumstemperatur. Man tillsätter sedan droppe för droppe vid 0°C en lösning av 5 g 1.8-dihydroxi-antrakinon i 100 cm: vattenfri tetrahydrofuran (THF). Han rör under 4 timmar vid rumstemperatur. varefter man surgör lösningen ned 75 cm3 åttiksyra. Han häller i 500 cn3 vatten och man extraherar med hjälp av diklorometan. Den organiska fasen torkas över magnesiumsulfat. koncentreras sedan under sänkt tryck. Den önskade produkten renas genom kronatografí på sílíkagel. Han erhåller sålunda 1 g gula kristaller av l0-[(N-2",2"-di- metyl-propanoyl)-2'-amino-fenyl]-1.8.10-trihydroxí-antron med smänpunxn 2s7_2s9°c.Example 1 Preparation of 1,8-dihydroxy-10-ERN-2 ", 2" -dimethyl-pro- panovyl) -2'-amino-phenyl] -antrone. a) To 18 g of N-pivaloylaniline in 100 cm 3 of tetrahydrofuran (THF) anhydrous is set at 0 ° C under inert atmosphere 100 cm 3 n-butyl-lithium (2.5 h). 10 15 20 25 30 35 n 459 807 After addition, the reaction mixture is left for 24 hours at room temperature. You then add drop by drop 0 ° C a solution of 5 g of 1,8-dihydroxy-anthraquinone in 100 cm: anhydrous tetrahydrofuran (THF). He touches for 4 hours room temperature. after which the solution is acidified down to 75 cm3 acetic acid. He pours in 500 cn3 of water and extracts using dichloromethane. The organic phase is dried over magnesium sulfate. then concentrated under reduced pressure. The desired product is purified by chronatography on silica gel. He thus obtaining 1 g of yellow crystals of 10 - [(N-2 ", 2" -di- methyl-propanoyl) -2'-amino-phenyl] -1,8,10-trihydroxy-anthrone with melting point 2s7_2s9 ° c.
NHR-spektrat överensstämmer med strukturen hos den förväntade produkten.The NHR spectrum is consistent with the structure of the expected the product.
Elementaranalys: C25H2305N Beräknat : C 71.92, H 5,55. 0 19,16. N 3,35 Funnet: 71.71 5.56 18.92 3.43 b) Till en suspension av 250 mg 10-f(N-2".2"-dímetyl-pro- panoyl)-2'-amino-fenyfl]-1,8,10-trihydroxi-antron, erhållen ovan under (a) i 25 cm3 isättika sätter man under inert at- mosfär 400 mg tenn(II)kloríd och några droppar koncentrerad saltsyra.Elemental analysis: C 25 H 21 O 5 N Calculated: C 71.92, H 5.55. 0 19.16. N 3.35 Found: 71.71 5.56 18.92 3.43 b) To a suspension of 250 mg of 10-f (N-2 ".2" -dimethyl-pro- panoyl) -2'-amino-phenyl -1] -1,8,10-trihydroxy-anthrone, obtained above under (a) in 25 cm3 of glacial acetic acid is placed under inert moss sphere 400 mg tin (II) chloride and a few drops concentrated hydrochloric acid.
Man rör under 2 timmar vid rumstemperatur. varefter reaktions- blandningen hälles i 100 cm3 vatten. Den önskade produkten faller ut och filtreras. torkas sedan. Han återuppta: sedan med hjälp av 50 cn3 diklorometan. som man rör i närvaro av 2 g kiselsyra. Lösningen filtreras. koncentreras sedan under sänkt tryck. Den önskade produkten utfälles genom tillsats av hexan. centrifugeras. torkas sedan. Man erhåller sålunda 100 mg gula kristaller med smältpunkt l76~l77°C.Stir for 2 hours at room temperature. after which the reaction the mixture is poured into 100 cm3 of water. The desired product falls out and is filtered. then dried. He resume: then using 50 cn3 dichloromethane. which is stirred in the presence of 2 g silicic acid. The solution is filtered. then concentrated below reduced pressure. The desired product is precipitated by the addition of hexane. centrifuged. then dried. You thus obtain 100 mg of yellow crystals, m.p. 176 DEG-177 DEG.
NHR-spektrat överensstämmer med strukturen hos den önskade produkten precis som masspektrat m/e 401. 10 15 20 25 30 35 459 807 12 Exempel 2 Framstâllninq av 1,8-díhvdroxí-10-(2'.4'-dinetoxí-fenvl)-antron a) Till en lösning av 22.1 g 1.3-dímetoxí-bensen i lösning i 50 cm3 vattenfri etyleter sätter man 100 cnz n-butyl-lí- tíum (1,6 M) vid rumstemperatur under argon. Efter 24 timmar försättes denna lösning snabbt med en suspension av 5 g 1,8- . . _ _ 3 _ _ -d1hydrox1-antraklnon 1 150 cm vattenfrl THF v1d en tempe- ratur vid -70°C. Efter avslutad omsättning surgör man reak- tíonsblandníngen med hjälp av S0 ena isättika. Efter tvätt med vatten (200 cm ) och torkning över magnesiumsulfat kon- centreras den organiska fasen under sänkt tryck. genom kromatografí av ett gult pulver renas sedan på sílíkagel. Han erhåller sålunda 200 mg av 10-(2',4'-dímetoxi-fenyl)-1,8,l0-tri- hydroxí-antron med smältpunkt 207°C.The NHR spectrum corresponds to the structure of the desired one the product just like mass spectrum m / e 401. 10 15 20 25 30 35 459 807 12 Example 2 Preparation of 1,8-dihydroxy-10- (2 ', 4'-dinethoxy-phenyl) -anthrone a) To a solution of 22.1 g of 1,3-dimethoxybenzene in solution i 50 cm 3 of anhydrous ethyl ether are added 100 cnz of n-butyl ten (1.6 M) at room temperature under argon. After 24 hours this solution is rapidly added with a suspension of 5 g of 1.8- . . _ _ 3 _ _ -d1hydrox1-anthraclonone 1 150 cm 3 of anhydrous THF at a temperature temperature at -70 ° C. After the sale is completed, the reaction is acidified. the mixture with the aid of S0 one glacial acetic acid. After washing with water (200 cm) and drying over magnesium sulphate the organic phase is centered under reduced pressure. by chromatography of a yellow powder then cleaned on silica gel. He thus receives 200 mg of 10- (2 ', 4'-dimethoxy-phenyl) -1,8,10-tri- hydroxy-anthrone, m.p. 207 ° C.
NHR-spektrat lH 250 MH: överensstämmer med strukturen hos den förväntade produkten.NHR spectrum 1H 250 MH: corresponds to the structure of the expected product.
Elementaranalvs: C H O 22 18 6 Beräknat: C 69.85 H 4.79 Funnet: 70.54 4,85 b) Till en lösning av 100 mg 10-(2'.4'-dínetoxi-fenyl)-1,8.10- -tríhydroxí-antron; såsom den erhölls under (a) här ovan í 25 cm ísättika sätter man under ínert atmosfär 200 mg tenn(II)k1oríd och nâgra droppar koncentrerad saltsyra. Reak- tíonsblandníngen röres under 5 timmar vid rumstemperatur. häl- les sedan i 100 cm3 vatten, som har till följd att den öns- kade produkten faller ut. som sedan filtreras och torkas. Han erhåller sålunda 50 mg av ett krâmfärgat pulver. vars smält- punkt är 15200.Elemental analysis: C H O 22 18 6 Calculated: C 69.85 H 4.79 Found: 70.54 4.85 b) To a solution of 100 mg of 10- (2'.4'-dinethoxy-phenyl) -1,8.10- -trihydroxy-anthron; as obtained in (a) above 25 cm of glacial acetic acid is placed under an inert atmosphere 200 mg tin (II) chloride and a few drops of concentrated hydrochloric acid. Reactive The mixture is stirred for 5 hours at room temperature. heel- then read in 100 cm3 of water, which results in the desired the product falls out. which is then filtered and dried. He thus obtaining 50 mg of a cream-colored powder. whose molten point is 15200.
Masspektrum mle : 362.Mass spectrum mle: 362.
Exempel 3 Framställning av 1,8-díhvdroxí-10-(4'-metoxí-fenyl)-antron 10 15 20 25 30 '35 13 459 807 a) Till en lösning av 28 g para-bromanísol i 50 ens vatten- fri tetrahydrofuran sätter man vid -78°C och under argon 100 cms N-hutyl-lítíum (1,6 M). Han låter lösningen återgå till rumstemperatur under l timme. Man häller den i en hronanpull och man tillsätter en suspension av 7.2 g l.8-dihydroxi-antra- kinon i 300 cm3 vattenfri THF vid en temperatur av -78°C och under argon. Efter avslutad tillsats låter nan reaktions- blandníngen återgå till rumstemperatur under 24 tinnar. Han surgör sedan reaktionsblandningen med hjälp av S0 cn3 isåt- tíka och man häller i S00 cm3 vatten.Example 3 Preparation of 1,8-dihydroxy-10- (4'-methoxy-phenyl) -anthrone 10 15 20 25 30 '35 13 459 807 a) To a solution of 28 g of para-bromoanisole in 50 even aqueous free tetrahydrofuran is set at -78 ° C and below argon 100 cms N-hutyl-lithium (1.6 M). He lets the solution return to room temperature below 1 hour. You pour it into a hronan pull and a suspension of 7.2 g of 1,8-dihydroxy-anthra- quinone in 300 cm 3 of anhydrous THF at a temperature of -78 ° C and under argon. Upon completion of the addition, the reaction the mixture returns to room temperature below 24 tins. He then acidifies the reaction mixture with the aid of SO tíka and you pour in S00 cm3 of water.
Efter extraktíon med hjälp av diklormetan torkas den organiska fasen över magnesiumsulfat. koncentreras sedan under sänkt tryck.After extraction with the aid of dichloromethane, the organic is dried phase over magnesium sulphate. then concentrated under lowered print.
Han erhåller sålunda efter kromatografí på sílíkagel 3.4 g önskad produkt. Efter omkristallísation i en blandning av toluen-hexan erhåller man gula kristaller av l0-(4'-metoxi- -fenyl)-1.8.l0-tríhydroxí-antron med smältpunkt 172-17300.He thus receives after chromatography on silica gel 3.4 g desired product. After recrystallization from a mixture of toluene-hexane to give yellow crystals of 10- (4'-methoxy- -phenyl) -1.8.10-trihydroxy-anthrone, m.p. 172-17300.
NHR-spektrat överensstämmer med strukturen hos den önskade produkten.The NHR spectrum corresponds to the structure of the desired one the product.
Elementaranalys: C H 0 21 16 S Beräknat: C 72.40 H 4.63 0 22.97 Funnett 72.47 4.61 22.87 b) Till en suspension av 200 mg 10-(4-metoxi-fenyl)-1.8.10- -tríhydroxi-antron. såsom den erhålles under (a) ovan. i 10 cm3 isättíka sätter man 200 mg tenn(II)kloríd och några droppar koncentrerad saltsyra. Han fortsätter olrörningen under ínert atmosfär under 2 timmar. Den önskade produkten er- hålles genom utfällníng av reaktíonsmedíumet i 100 ena vat- ten. Man erhåller sålunda 150 mg av ett gult grönaktígt pul- ver. som sönderfaller från 215°C. nun-Spektra: och masspextrat (m/e = 332) överensstämmer med strukturen hos den önskade produkten. 10 15 20 25 30 35 459 807 14 Elementaranalys: C 1 H16 04 Beräknat: C 75.89 H 4.85 O 19.25 Funnet: 75.78 4.80 19.26 Exemgel 4 Framställníng av lJ8-díhvdroxí-10-(3'-trífluoronet1l-fen1l)- -antron a) Till en lösning av 25 g 3-trífluorometyl-bronobensen i 100 ml vattenfri THF sätter man 100 cma n-butyl-lítíun (1,6 H) _ o v1d -78 C under argon.Elemental analysis: C H 0 21 16 S Calculated: C 72.40 H 4.63 0 22.97 Found 72.47 4.61 22.87 b) To a suspension of 200 mg 10- (4-methoxy-phenyl) -1.8.10- -trihydroxy-anthron. as obtained under (a) above. i 10 cm3 of glacial acetic acid, 200 mg of stannous chloride and a few are added drops of concentrated hydrochloric acid. He continues the ol 'movement under an inert atmosphere for 2 hours. The desired product is obtained by precipitating the reaction medium in 100 units of water. ten. 150 mg of a yellow greenish powder are thus obtained. ver. which decomposes from 215 ° C. nun-Spectra: and mass spectra (m / e = 332) correspond to the structure of the desired product. 10 15 20 25 30 35 459 807 14 Elemental analysis: C 1 H 16 04 Calculated: C 75.89 H 4.85 O 19.25 Found: 75.78 4.80 19.26 Exemgel 4 Preparation of 1,8-dihydroxy-10- (3'-trifluoronethyl-phenyl) - -antron a) To a solution of 25 g of 3-trifluoromethyl-bronobenzene in 100 ml of anhydrous THF is added 100 cma n-butyl lithium (1.6 H) _ o v1d -78 ° C under argon.
Efter avslutad tillsats låter man reaktionsmedíumet återgå till rumstemperatur.After the addition is complete, the reaction medium is allowed to return to room temperature.
Den erhållna lösningen försattes sedan. droppe för droppe un- der ínert atmosfär, med en suspension av 7.2 g 1.8-díhydroxí- -antrakínon i 200 cm3 vattenfri THF vid -78°C.The resulting solution was then added. drop by drop un- inert atmosphere, with a suspension of 7.2 g of 1,8-dihydroxy -anthraquinone in 200 cm 3 of anhydrous THF at -78 ° C.
Reaktíonsblandningen hålles vid denna temperatur under 1 tim- ma. bríngas sedan till rumstemperatur. göres sedan genom tillsats av 50 cma ísättíka. Reaktíonsme- diumet tvättas med 200 cma vatten. torkas.The reaction mixture is kept at this temperature for 1 hour. ma. then brought to room temperature. is then made by adding 50 cma of glacial acetic acid. Reaction the dium is washed with 200 cm 3 of water. torkas.
Reaktionslösníngen sur- koncentreras. rengörs sedan på silíkagelkolonn. Man isolerar 1.2 g önskad produkt, som man omkrístallíserar i en blandning av toluen- -nexan. Han erhåller gula kristaller av l0-(3'-tríf1uoro- metyl-fenyl)-1.8.10-tríhydroxí-antron med smältpunkt 222-223°c.The reaction solutions are concentrated. then cleaned on silica gel column. Isolate 1.2 g desired product, which is recrystallized from a mixture of toluene -nexan. He receives yellow crystals of 10- (3'-trifluoro- methyl-phenyl) -1.8.10-trihydroxy-anthrone with melting point 222-223 ° C.
NHR-spektratlfl 250 Mhz överensstämmer med strukturen hos den önskade produkten.NHR spectrum fl 250 Mhz corresponds to its structure desired product.
Elementaranalysz C F O 21 H13 3 4 'seräxnauz c 65,30 H 3.39 Funnet: 64,95 3.35 b) Till en lösning av 150 mg 10-(3-trífluorometyl-fenyl)- -1,8,10-tríhydroxí-antron, såsom den erhålles under (a) här 10 15 20 25 30 35 OVBII , H 459 807 i 25 cma isättíksyra. placerad under kväve. sätter man 200 mg tenn(II)klorid och nâgra droppar koncentrerad saltsyra.Elemental analysis C F O 21 H13 3 4 'seräxnauz c 65.30 H 3.39 Found: 64.95 3.35 b) To a solution of 150 mg of 10- (3-trifluoromethyl-phenyl) - -1,8,10-trihydroxy-anthron, as obtained under (a) herein 10 15 20 25 30 35 OVBII, H 459 807 in 25 cm 3 of glacial acetic acid. placed under nitrogen. you put 200 mg of stannous chloride and a few drops of concentrated hydrochloric acid.
Reaktionsblandningen omröres under 3 timmar vid rumstempera- tur. varefter man fäller ut den önskade produkten under till- sats av 100 ena vatten. Produkten filtreras. torkas sedan.The reaction mixture is stirred for 3 hours at room temperature. lucky. after which the desired product is precipitated during batch of 100 one water. The product is filtered. then dried.
Man erhåller S0 mg av en gul produkt. vars smältpunkt är 210-211°c.S0 mg of a yellow product is obtained. whose melting point is 210-211 ° C.
Masspektrum : mle : 370 Exempel 5 Framställniníng av 1.8-dihydroxi-10-(3'-metoxi-fenyl)-antron a) Orqanomagnesiummetoden Till 2,7 g magnesium i 40 cm3 vattenfri THF sätter man under kväve 20.8 g m-bromoanísol under återloppskokning av THF. Återloppet upprätthâlles 1 timme efter avslutad tillsats.Mass spectrum: m / e: 370 Example 5 Preparation of 1,8-dihydroxy-10- (3'-methoxy-phenyl) -anthrone a) The organomagnesium method To 2.7 g of magnesium in 40 cm 3 of anhydrous THF is added nitrogen 20.8 g of m-bromoanisole under reflux of THF. The reflux is maintained for 1 hour after the addition is complete.
Reaktionsblandningen sättes sedan droppe för droppe till en suspension av 5,9 1.8-díhydroxí-antrakinon i 60 cm3 vatten- fri THF under kväve och vid 0°C. Reaktionsblandningen lämnas över natt vid rumstemperatur. värmes sedan under 8 timmar vid so°c.The reaction mixture is then added dropwise to one suspension of 5,9 1,8-dihydroxy-anthraquinone in 60 cm 3 of aqueous free THF under nitrogen and at 0 ° C. The reaction mixture is left overnight at room temperature. then heated for 8 hours at so ° c.
Man surgör reaktionsblandníngen genom tillsats av 9 cm3 ís- ättika, varefter man tillsätter 150 cm3 vatten. Man extrahe- rar produkten med etyleter (100 cm3). och den organiska fa- sen torkas. koncentreras sedan under vakuum. Reaktionsbland- ningen renas sedan genom kromatografi på silikagel och man er- håller 1,2 g 10-(3'-metoxí-fenyl)-l.8.10-trihydroxi-antron.The reaction mixture is acidified by adding 9 cm3 of ice. vinegar, after which 150 cm3 of water are added. Man extrahe- the product with ethyl ether (100 cm 3). and the organic then dried. then concentrated in vacuo. Reaction mixture The residue is then purified by chromatography on silica gel to give contains 1.2 g of 10- (3'-methoxy-phenyl) -1,8,10-trihydroxy-anthrone.
NH-spektrat samt masspektrat (m/e = 348) överensstämmer med strukturen hos den önskade produkten. a') Metoden med organolítiumförening . . . 3 .NH spectra and mass spectra (m / e = 348) correspond to the structure of the desired product. a ') The organolithium compound method . . . 3.
Till en lösning av 28 g m-bromoanisol 1 50 cm vattenfri THF sätter man vid -78°C under argon 100 cm3 n-butyllitium 10 15 20 25 30 35 459 807 15 (1,6 H). Man låter sedan reaktionslösningen återgå till rums- temperatur under l timme. Den erhållna lösningen överföras se- dan till en bromampull och försåttes med en suspension av 7.2 g 1.8-díhydroxi-antrakinon i 300 cna vattenfri THF vid -7a°c och under argon. Efter avslutad tillsats låter man reaktionsblandníngen återgå till rumstemperatur under 24 tim- mar. Han surgör sedan med hjälp av 50 ena man tvättar med S00 cm3 vatten. ras, isättika. varefter Den organiska fasen separe- torkas sedan över magnesíumsulfat och koncentreras under sänkt tryck. Den önskade produkten krístalliserar genom till- sats av toluen. Han isolerar sålunda 4.2 g l0-(3'-metoxí- -fenyl)-1.8.10-trihydroxi-antron med snältpunkt 202°C.To a solution of 28 g of m-bromoanisole 1 50 cm 3 of anhydrous THF at -78 ° C under argon 100 cm 3 of n-butyllithium are added 10 15 20 25 30 35 459 807 15 (1.6 H). The reaction solution is then allowed to return to room temperature. temperature below 1 hour. The solution obtained is transferred separately. and a suspension of 7.2 g 1,8-dihydroxy-anthraquinone in 300 cna of anhydrous THF at -7a ° c and under argon. After the addition is complete, you let go the reaction mixture is returned to room temperature for 24 hours. mar. He then acidifies with the help of 50 ones you wash with S00 cm3 of water. race, glacial acetic acid. after which The organic phase separates then dried over magnesium sulfate and concentrated reduced pressure. The desired product crystallizes by adding rate of toluene. He thus isolates 4.2 g of 10- (3'-methoxy) -phenyl) -1.8.10-trihydroxy-anthron with melting point 202 ° C.
NHR-spektrat överensstämmer med strukturen hos den önskade produkten.The NHR spectrum corresponds to the structure of the desired one the product.
Elementaranalysz C H O Zl 16 5 Beräknat: C 72.40 H 4.63 0 22.97 Funnet: 72.73 4.61 22.62 b) Till en lösning av 3 g 10-(3'-metoxi-fenyl)-1.8.l0-tríhydr- oxi-antron, såsom den erhölls enligt en av metoderna ovan un- der (a) eller (a') i ca 100 cma ísättíka. hållen under inert . 3 atmosfär sätter man 3 g tenn(II)klor1d. sedan 3 cm koncent- rerad saltsyra. Reaktionsblandningen omföres sedan under 2 timmar vid rumstemperatur. varefter den önskade produkten ut- fälles genom tillsats av 500 cm3 vatten. Efter torkning er- håller man 2.7 g av ett gult pulver vars smältpunkt är 187°C.Elemental analysis C H O Zl 16 5 Calculated: C 72.40 H 4.63 0 22.97 Found: 72.73 4.61 22.62 b) To a solution of 3 g of 10- (3'-methoxy-phenyl) -1.8.10-trihydride oxy-anthron, as obtained by one of the above methods der (a) eller (a ') i ca 100 cma ísättíka. kept below inert . 3 atmosphere add 3 g of tin (II) chlor1d. then 3 cm hydrochloric acid. The reaction mixture is then stirred under 2 hours at room temperature. after which the desired product precipitate by adding 500 cm 3 of water. After drying, 2.7 g of a yellow powder with a melting point of 187 ° C are kept.
NHR-spektrat överensstämmer med strukturen hos den önskade produkten.The NHR spectrum corresponds to the structure of the desired one the product.
Elementaranalys: 0 C21 H16 4 Beräknat: C 75.89 H 4.85 O 19,25 Funnet: 75.71 4.92 19.24 Exemèel 6 Framställnina av 1,8-díhydroxí-10-(3'-hvdroxí-fenyl)-antron 10 15 20 25 30 35 17 459 807 Han sätter 500 mg 1.8-díhydroxi-10-(3'-netoxi-fenyl)-antron. ät- tiksyra och 17 cm3 bromvätesyra under inert atnosfär. Man värmer till 100-ll0°C och man följer omsättníngens utveck- såsom den erhölls i exempel 5 till en lösning av 35 cm3 ling genom tunnskíktskromatografí. Sedan utgångsprodukten fullständigt försvunnit hälles lösningen på ca 200 cn3 vat- ten, och fällníngen filtreras. Efter torkning löses produkten i 100 cm3 díklorometan. röres sedan i närvaro av 3 g kisel- syra. Lösningen filtreras, koncentreras sedan under sänkt tryck. Den önskade produkten kristalliserar genom tillsats av hexan. Man erhåller sålunda 310 mg gula kristallser med smält- punxt 2o4°c.Elemental analysis: 0 C21 H16 4 Calculated: C 75.89 H 4.85 O 19.25 Found: 75.71 4.92 19.24 Example 6 Preparation of 1,8-dihydroxy-10- (3'-hydroxy-phenyl) -anthrone 10 15 20 25 30 35 17 459 807 He puts 500 mg of 1,8-dihydroxy-10- (3'-netoxy-phenyl) -anthrone. eating tic acid and 17 cm3 of hydrobromic acid under an inert atmosphere. MAN warms to 100-110 ° C and the evolution of the reaction is followed. as obtained in Example 5 to a solution of 35 cm 3 by thin layer chromatography. Then the starting product completely disappeared, the solution is poured onto about 200 cn3 of water. and the precipitate is filtered. After drying, the product dissolves in 100 cm3 of dichloromethane. is then stirred in the presence of 3 g of silicon. acid. The solution is filtered, then concentrated under immersion print. The desired product crystallizes by adding hexane. There are thus obtained 310 mg of yellow crystals with molten point 2o4 ° c.
NHR-spektrat överensstämmer med strukturen hos den önskade produkten.The NHR spectrum corresponds to the structure of the desired one the product.
Elementaranalys: C20 H14 04 Beräknat: C 75,46 H 4.43 O 20,11 Funnett 75.57 4.37 19,96 Exempel 7 Framställníng av 1.8-dihydroxí-10-(2'-metoxi-fenyl)-antron a) Till 2.55 g magnesium i 15 cm3 vattenfri THF sätter man under kväve 16.2 g o-bromanisol under återlopp av THF. Åter- loppet upprätthålles under 1/2 timme efter avslutad tillsats.Elemental analysis: C20 H14 04 Calculated: C 75.46 H 4.43 O 20.11 Found 75.57 4.37 19.96 Example 7 Preparation of 1,8-dihydroxy-10- (2'-methoxy-phenyl) -anthrone a) To 2.55 g of magnesium in 15 cm 3 of anhydrous THF is added under nitrogen 16.2 g of o-bromoanisole under reflux of THF. Re- the course is maintained for 1/2 hour after the addition is complete.
Den erhållna lösningen försättes sedan droppe för droppe med en suspension av 5 g 1,8-díhydroxi-antrakínon i S0 cm3 vat- tenfri THF under kväve och vid 0°C. Reaktionsblandníngen lämnas under en natt vid rumstemperatur. surgöres sedan med 9 cm3 isättíka, som försatts med 150 ena vatten.The resulting solution is then added drop by drop a suspension of 5 g of 1,8-dihydroxyanthraquinone in thien-free THF under nitrogen and at 0 ° C. The reaction mixture left overnight at room temperature. then acidified with 9 cm3 of glacial acetic acid, which was added with 150 units of water.
Den organiska fasen dekanteras. tvättas två gânger'med vatten (100 cm3) torkas sedan över magnesiunsulfat. Lösningen kon- centreras sedan under vakuum. återupptages sedan med toluen.The organic phase is decanted. washed twice 'with water (100 cm 3) is then dried over magnesium sulphate. The solution con- then centered under vacuum. then resumed with toluene.
Lösningen filtreras genom tillsats av hexan. Man erhåller S g av en gul fällníng. som omkrístalliseras i en blandning av to- 10 15 20 25 30 35 459 807 N luen-hexan. De erhållna ljusgula kristallerna av 10-(2' oxi-fenyl)-1.8.10-trihydroxi 220-z21°c. -met- -antron har en smältpunkt på Elementaranalys: 0 C21 H16 s aeraxnar: c 12.40 H 4.63 o 22.97 Funnet: 72.59 4.65 23.21 b) Till en lösning av 2.8 g 10-(2'-metoxi-fenyl)-1.8.l0-tri- hydroxi-antron. såsom den erhållits under (a) här ovan. i 90 3 cm isättiksyra. hållen under inert atmosfär. sätter man 4,9 g tenn(II)kloríd, sedan 14.5 cn3 koncentrerad saltsyra.The solution is filtered by adding hexane. You get S g of a yellow precipitate. which is recrystallized from a mixture of 10 15 20 25 30 35 459 807 N luen-hexane. The resulting light yellow crystals of 10- (2 ' oxy-phenyl) -1.8.10-trihydroxy 220 DEG-21 DEG. -met- -antron has a melting point of Elemental analysis: 0 C21 H16 s aeraxnar: c 12.40 H 4.63 o 22.97 Found: 72.59 4.65 23.21 b) To a solution of 2.8 g of 10- (2'-methoxy-phenyl) -1.8.10-tri- hydroxy-anthron. as obtained under (a) above. i 90 3 cm glacial acetic acid. held under an inert atmosphere. you set 4.9 g of stannous chloride, then 14.5 cn3 of concentrated hydrochloric acid.
Reaktionsblandníngen omröres sedan vid rumstemperatur under 3 timmar. Den önskade produkten utfälles genom att reaktionsme- diumet hälles i 200 cms vatten Han erhåller sålunda 1 g ren produkt efter kromatografi på silikagel. De erhållna gula kristallerna har en smältpunkt på l9l°C.The reaction mixture is then stirred at room temperature for 3 hours hours. The desired product is precipitated by reacting the reaction medium with the dium is poured into 200 cm 3 of water. He thus obtains 1 g of pure product after chromatography on silica gel. The yellow obtained the crystals have a melting point of 191 ° C.
NHR-spektrat samt masspektrat (mle = 332) överensstämmer med strukturen hos den önskade produkten.NHR spectra and mass spectra (mle = 332) correspond to the structure of the desired product.
Elementaranalys: C 0 21 H16 4 Beräknat: C 75.89 H 4,85 0 19.25 Funnet: 75,96 4.92 19.30 Exempel 8 Framställning av l,8-díhvdroxi-l0-(2-tíenvl)-antron a) Till en lösning av 12.7 ena tiofen i 100 cm3 vattenfri etyleter sätter man 100 cma n-butyl-litíul (l.6 H) vid OOC under argon. Efter tillsats håller man lösningen vid 0°C un- der l timme, varefter man låter återgå till rumstemperatur.Elemental analysis: C 0 21 H16 4 Calculated: C 75.89 H 4.85 0 19.25 Found: 75.96 4.92 19.30 Example 8 Preparation of 1,8-dihydroxy-10- (2-thienyl) -anthron a) To a solution of 12.7 one thiophene in 100 cm3 of anhydrous ethyl ether is added 100 cm 3 of n-butyl-lithium (1.6 H) at 0 ° C under argon. After addition, the solution is kept at 0 ° C der l hour, after which it is allowed to return to room temperature.
Den erhållna lösningen sättes sedan droppe för droppe till en suspension av 9.2 g 1.8-dihydroxi-antrakinon i 1000 cm3 vat- tenfri THF vid -78°C under argon. Man låter reaktionsbland- ningen återgå till rumstemperatur. varefter man surgör med 50 cm3 isättika. 10 15 20 25 30 35 “ 459 807 Lösningen koncentreras under sänkt tryck. varefter den åter- upptages med etyleter. Den bildade bruna fällningen filtreras sedan. fördelas sedan i 100 cm3 varm etanol. Han erhåller sålunda gula kristaller av 10-(2-tienyl)-1.8,l0-trihydroxi- -antron med smältpunkt 191-19200.The resulting solution is then added dropwise to one suspension of 9.2 g of 1,8-dihydroxy-anthraquinone in 1000 cm3 of water tenfree THF at -78 ° C under argon. Reaction mixtures are allowed to return to room temperature. after which you acidify with 50 cm3 vinegar. 10 15 20 25 30 35 459 807 The solution is concentrated under reduced pressure. after which it taken up with ethyl ether. The brown precipitate formed is filtered then. then distributed in 100 cm3 of hot ethanol. He receives thus yellow crystals of 10- (2-thienyl) -1,8,10-trihydroxy- -antron with melting point 191-19200.
Elementaranalys: C H 04 S 18 12 Beräknat: C 66.65 H 3,73 D 9.89 Funnet: 66,20 3.66 9.10 b) Till en lösning av 5 g 10-(2-tienyl)-1.8.l0-trihydroxi- -antron, såsom den erhölls under (a) här ovan i 100 cm3 ät- tiksyra sätter man under inert atmosfär 14.6 g tenn(II)k1orid och 20 cma koncentrerad saltsyra. Han rör vid rumstemperatur under 2 timmar. varefter man häller lösningen på 200 cm3 vatten. Man filtrerar, torkar sedan den erhållna produkten.Elemental analysis: C H 04 S 18 12 Calculated: C 66.65 H 3.73 D 9.89 Found: 66.20 3.66 9.10 b) To a solution of 5 g of 10- (2-thienyl) -1,8-trihydroxy- -antron, as obtained in (a) above in 100 cm 3 of tic acid, 14.6 g of stannous chloride are placed under an inert atmosphere and 20 cm 3 of concentrated hydrochloric acid. He touches at room temperature for 2 hours. after which the solution is poured onto 200 cm3 water. It is filtered, then the product obtained is dried.
Man isolerar sålunda 4,55 g 1.8-dihydroxi-10-(2-tíenyl)-ant- ron, som efter omkristallisation i toluen har en smältpunkt på 181-1a2°c.4.55 g of 1,8-dihydroxy-10- (2-thienyl) -antene are thus isolated. which, after recrystallization from toluene, has a melting point of 181-1a2 ° c.
NHR-spektrat och masspektrat (m/e = 308) motsvarar strukturen hos den önskade produkten.NHR spectra and mass spectra (m / e = 308) correspond to the structure of the desired product.
Elementaranalysz C18 H12 03 S Beräknat: C 70.11 H 3.92 O 16.57 S 10.40 Funnet: 69.75 3.80 15.54 9.98 Exempel 9 Framställning av 1.8-dihvdroxi-10-(2-tiazolyl)~antron a) Till en lösning av 100 cm3 n-butyl-litiun (1.S M) i l00 cm3 vattenfri etyleter sätter man droppe för droppe vid -4000 under inert atmosfär 24,6 g 2-bromotiazol. Efter till- sats bringar man reaktionsblandningen till -78°C och man tillsätter 9,6 g 1.89-dihydroxi-antrakinon i lösning i 1000 cm3 THF. Man låter sedan reaktionsmediumet stå 48 timmar i rumstemperatur, Man surgör med hjälp av 50 cm3 ättiksyra. _ U _ 3 varefter man häller losningen på 1000 cm vatten. 10 15 20 25 30 35 459 807 2° Den organiska fasen torkas genom magnesiunsulfat. koncentreras sedan vid sänkt tryck. Den önskade produkten renas genom kro- matografi på sílikagel. Han isolerar sålunda 3.5 g 10-(2 zolyl)-1.8.10-trihydroxi-antron. som föreligger i gul fast substans. som onkristalliseras i toluen-nexan. -tia- forn av en en blandnin av Kristallerna har en smältpunkt av 223-225°C, NHR-spektrat samt masspektrat (nle = 325) överensstämmer med strukturen hos den önskade produkten.Elemental analysis C18 H12 03 S Calculated: C 70.11 H 3.92 O 16.57 S 10.40 Found: 69.75 3.80 15.54 9.98 Example 9 Preparation of 1,8-dihydroxy-10- (2-thiazolyl) anthrone a) To a solution of 100 cm3 of n-butyl-lithium (1.S M) i l00 cm3 anhydrous ethyl ether is added drop by drop -4000 under inert atmosphere 24.6 g of 2-bromothiazole. After the reaction mixture is brought to -78 ° C and add 9.6 g of 1,89-dihydroxy-anthraquinone in solution in 1000 cm3 THF. The reaction medium is then allowed to stand for 48 hours room temperature, Acidification is carried out using 50 cm3 of acetic acid. _ U _ 3 after which the solution is poured onto 1000 cm of water. 10 15 20 25 30 35 459 807 2 ° The organic phase is dried over magnesium sulphate. concentrated then at reduced pressure. The desired product is purified by matography on silica gel. He thus isolates 3.5 g 10- (2 zolyl) -1.8.10-trihydroxy-anthron. contained in yellow solid. which is recrystallized in toluene-nexan. -ten- forn of one a mixture of The crystals have a melting point of 223-225 ° C, NHR spectra and mass spectra (nle = 325) correspond to the structure of the desired product.
Elementaranalys: C H 17 ll N 04 S Beräknat: C 62,76 H 3,42 O 19.67 N 4,30 S 9,86 Funnett 62.85 3.41 19.63 4.39 9.66 b) Till en suspension av 2 g 10-(2-tíazolyl)-1.8.lO-trihydr- oxi-antron. såsom den erhölls under (a) här ovan i 75 ena ättiksyra sätter man 2 g metallískt tenn och 25 ena salt- syra. Han värmer blandningen på vattenbad under 1 timme, var- vid utgångsprodukten fullständigt går i lösning. Han häller på 200 cmz vatten. filtrerar sedan den erhållna produkten. erhåller sålunda 1 g 1,8-dihydroxi-l0-(2-tiazolyl) man omkrístalliserar í Han -antron. som metanol. Den omkristalliserade produk- tens smältpunkt är l42°C.Elemental analysis: C H 17 ll N 04 S Calculated: C 62.76 H 3.42 O 19.67 N 4.30 S 9.86 Funnett 62.85 3.41 19.63 4.39 9.66 b) To a suspension of 2 g of 10- (2-thiazolyl) -1,8,10-trihydrate oxy-anthron. as obtained under (a) above in 75 acetic acid add 2 g of metallic tin and 25 acid. He heats the mixture in a water bath for 1 hour, each at the starting product completely goes into solution. He pours on 200 cmz water. then filters the product obtained. thus gives 1 g of 1,8-dihydroxy-10- (2-thiazolyl) man recrystallizes in He -antron. as methanol. The recrystallized product melting point is 142 ° C.
Elementaranalysz C N 0 S 17 H11 3 Beräknat: C 66,00 H 3,58 N 4.52 O 15,51 S 10,35 Funnet: 66.15 3,60 4.60 15.92 10.15 Bxemgel 10 Framställninq av 10-(3'-metoxi-fenvl)-1.8.9-triacetoxí-antracen I en trehalsad kolv försedd med magnetourörare. kväveinlopp. rör man 200 mg 10-(3'-metoxi-fenyl)-1.8-dihydroxi-antron. er- hållet en1igt'exempel 5, i 5 cm3 vattenfri ättiksyra och några droppar pyridín. Blandningen röres vid 80°C under 3 timmar, varefter den kyles. Den önskade triestern kristallise- rar och centrifugeras, varefter den tvättas med hexan. Man er- håller 150 mg ljusgula kristaller med smältpunkt 278°C. 10 15 20 25 30 35 21 459 807 Elementaranalysz C H 0 27 22 7 Beräknat: C 70.73 H 4,84 0 24.43 Funnet: 70,47 5.01 24.24 Exempel ll Framställnin av 10-(3'~metoxi-fenyl)-1.8.9-trípropanovloxi- -antracen 4 I en trehalsad kolv försedd med en magnetomrörare rör man 250 mg 10-(3'-metoxí-fenyl)-1.8-dihydroxí-antron. erhållen en- ligt exempel 5 i 5 cm3 propionsyraanhydrid och några droppar pyridín. Blandningen omrörs vid 80°C under 6 tinnar under ínert atmosfär.Elemental analysis C N 0 S 17 H11 3 Calculated: C 66.00 H 3.58 N 4.52 O 15.51 S 10.35 Found: 66.15 3.60 4.60 15.92 10.15 Bxemgel 10 Preparation of 10- (3'-methoxy-phenyl) -1.8.9-triacetoxy-anthracene In a three-necked piston equipped with magnetour stirrer. nitrogen inlet. stir 200 mg of 10- (3'-methoxy-phenyl) -1,8-dihydroxy-anthron. your- held according to Example 5, in 5 cm 3 of anhydrous acetic acid and a few drops of pyridine. The mixture is stirred at 80 ° C for 3 hours hours, after which it is cooled. The desired triester crystallizes and centrifuged, after which it is washed with hexane. You are- holds 150 mg of light yellow crystals, m.p. 278 ° C. 10 15 20 25 30 35 21 459 807 Elemental analysis C H 0 27 22 7 Calculated: C 70.73 H 4.84 0 24.43 Found: 70.47 5.01 24.24 Example ll Preparation of 10- (3 '- methoxy-phenyl) -1.8.9-tripropanovloxy- -anthracene 4 In a three-necked flask equipped with a magnetic stirrer, stir 250 mg 10- (3'-methoxy-phenyl) -1,8-dihydroxy-anthrone. received a Example 5 in 5 cm 3 of propionic anhydride and a few drops pyridine. The mixture is stirred at 80 ° C for 6 hours inner atmosphere.
Lösningen hälles i 100 cm3 vatten, extraheras med eter, se- dan med en vattenlösníng av natriumbíkarbonat. Han torkar se- dan över magnesiumsulfat, koncentrerar sedan under sänkt tryck. Han isolerar 200 mg av den önskade tríestern genom tillsats av hexan.The solution is poured into 100 cm 3 of water, extracted with ether, with an aqueous solution of sodium bicarbonate. He dries se- over magnesium sulfate, then concentrate under lowered print. He isolates 200 mg of the desired triester through addition of hexane.
De erhållna gula kristallerna har en smältpunkt på 177-l78°C. NHR-spektrat och masspektrat (m/e : 500) motsva- rar strukturen hos den önskade produkten.The yellow crystals obtained have a melting point of 177-178 ° C. NHR spectra and mass spectra (m / e: 500) correspond to the structure of the desired product.
Exempel 12 Framställnínq av 10-(2-tíenvl)-1,8.9-tríacetoxi-antracen I en trehalsad kolv försedd med en magnetomrörare rör man 250 mg 10-(2-tíenyl)-1.8-díhydroxí-antron. erhållen enligt exempel 8. i S cm3 ättíksyraanhydrid och några droppar pyrídín.Example 12 Preparation of 10- (2-thienyl) -1,8.9-triacetoxy-anthracene In a three-necked flask equipped with a magnetic stirrer, stir 250 mg 10- (2-thienyl) -1,8-dihydroxy-anthron. obtained according to examples 8. in S cm3 acetic anhydride and a few drops of pyridine.
Blandningen röres 3 timmar vid 80°C under inert atmosfär. varefter kyles. Den önskade trí-estern kristalliserar och centrifugeras sedan och tvättas med hexan. Han erhåller sålun- da 300 mg ljusgula kristaller med smältpunkt 260°C.The mixture is stirred for 3 hours at 80 ° C under an inert atmosphere. after which it is cooled. The desired triester ester crystallizes and then centrifuged and washed with hexane. He thus receives da 300 mg light yellow crystals, m.p. 260 ° C.
Elementaranalys: C24 H18 06 S Beräknat: C 66.35 H 4.17 O 22.10 S 7,38 Funnet: 66,35 4,19 22,20 7.26 10 15 20 25 30 35 459 807 22 Exempel 13 Framställning av 10-(2-tíenvl)-1,8,9-tripro Danoyloxi-antracen I en trehalsad kolv försedd med en magnetonrörare rör man 250 mg 10-(2-tienyl)-1.8-dihydroxi -antron erhållen enligt exempel 8 i 5 cm3 propionsyraanhydrid och nâgra droppar pyridin.Elemental analysis: C24 H18 06 S Calculated: C 66.35 H 4.17 O 22.10 S 7.38 Found: 66.35 4.19 22.20 7.26 10 15 20 25 30 35 459 807 22 Example 13 Preparation of 10- (2-thienyl) -1,8,9-tripro Danoyloxy anthracene In a three-necked flask equipped with a magneton stirrer, stir 250 mg 10- (2-thienyl) -1,8-dihydroxy -antrons obtained according to examples 8 i 5 cm3 of propionic anhydride and a few drops of pyridine.
Blandningen omröres vid 80°C under 6 timmar under kväve.The mixture is stirred at 80 ° C for 6 hours under nitrogen.
Genom kylning utfaller den önskade produkten. Han isolerar 120 mg gula kristaller. Filtratet hälles i 100 cn3 vatten, ext- raheras med eter. tvättas med en vattenlösning av natríunbí- karbonat. varefter eterfasen torkas och koncentreras under sänkt tryck. Genom tillsats av hexan till återstoden erhåller man ytterligare 130 mg av den önskade tri-estern. De ljusgula kristallerna har en smältpunkt på l92°C. NHR-spektrat och masspektrat (m/e : 476) motsvarar strukturen hos den önskade produkten.Cooling results in the desired product. He isolates 120 mg yellow crystals. The filtrate is poured into 100 cn3 of water, ext- raheras with ether. washed with an aqueous solution of sodium carbonate. after which the ether phase is dried and concentrated underneath reduced pressure. By adding hexane to the residue obtained an additional 130 mg of the desired triester. The light yellow ones the crystals have a melting point of 192 ° C. NHR spectrum and mass spectrum (m / e: 476) corresponds to the structure of the desired one the product.
Exempel 14 Framställníng av 1.8-dípivaloyloxi-10-(2'-tienvl)-antron Till en lösning omrörd vid normal temperatr under skydd av ljus och luftfuktighet av 2 g 10-(2'-tienyl)-l.8-dihydroxi- -antron 1 150 ena vattenfri toluen sätter man fen ekvivalen- ter pyridin och omedelbart efter fem molekvivalenter pivaloyl- kloríd. Reaktíonshlandningen bringas därefter till återlopp 8 timmar, under vilken tid hela utgångsprodukten omvandlas.Example 14 Preparation of 1,8-dipivaloyloxy-10- (2'-thienyl) -anthrone To a solution stirred at normal temperature under the protection of light and humidity of 2 g of 10- (2'-thienyl) -1,8-dihydroxy- -antron 1 150 one anhydrous toluene one sets the fin equivalent- pyridine and immediately after five molar equivalents of pivaloyl chloride. The reaction mixture is then brought to reflux 8 hours, during which time the entire starting product is converted.
Reaktionsmediumet koncentreras sedan under sänkt tryck. åter- upptages med vatten och extraheras med metylenklorid.The reaction medium is then concentrated under reduced pressure. re- taken up with water and extracted with methylene chloride.
Metylenkloridfasen tvättas med vatten, magnesiumsulfat och koncentreras. dekanteras, torkas över Den erhållna fasta substansen omkristallíseras i en blandning av hexan-etylacetat. Han erhåller 1.5 g gula kristaller. som smälter vid 17o°. 10 15 20 25 30 35 23 459 807 NM- och mass-spektrana (m/e : 476)motsvarar strukturen hos den önskade produkten.The methylene chloride phase is washed with water, magnesium sulfate and concentrated. decanted, dried over The resulting solid is recrystallized from a mixture of hexane-ethyl acetate. He receives 1.5 g of yellow crystals. as melts at 17 °. 10 15 20 25 30 35 23 459 807 The NM and mass spectra (m / e: 476) correspond to the structure of the desired product.
Farmaceutiska och kosmetiska kompositioner Exempel 1 Kagslar innehållande 0,5 g pulver I kapslar bestående av gelatín. titandioxid och konserveríugs- medel kondítionera: man 0.5 g av följande pulver: - 1,8-díhydroxí-10-(2'-metoxí-fenyl)-antron . . . . . . . . . ....0.3 g - potatisstärke1se.... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ..0.1 g - laktos g.s.p . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ..0,5 g Exempel 2 Man har framställt tabletter om 1 g utgående ifrån blandningen av följande ingredienser: _ 1.8-dihydroxi-10-(2-tíenyl)-antron . . . . . . . .............0.4 g - polyvinylpyrro1idon.......... . . . . . . . . . . . . . . . . . . . . . . . ..0.0l3 g L tvärbunden polyvinylpyrrolidon . . . . . . . . . . . .............0.0S g - talk.. . . . . . _... . . . . . ................ . . . . ..............0.08 g - kíselsyra “Aerosil 200" tillhandahållen av sté DEGUSSA0.001 g - laktos q.s.p..........................................100 g I detta exempel kan l,8-dihydoxí-10-(2-tienyl)-antronen ersät- tas med en ekvívalent mängd av 1.8-dihydroxi-l0(3'-metoxí- -fenyl)-antron.Pharmaceutical and cosmetic compositions Example 1 Kagslar containing 0.5 g of powder In capsules consisting of gelatin. titanium dioxide and preservatives conditioner: 0.5 g of the following powder: 1,8-Dihydroxy-10- (2'-methoxy-phenyl) -anthrone. . . . . . . . . .... 0.3 g - potatisstärke1se ..... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ..0.1 g - lactose g.s.p. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ..0.5 g Example 2 1 g tablets have been prepared from the mixture of the following ingredients: 1,8-Dihydroxy-10- (2-thienyl) -antrone. . . . . . . ............. 0.4 g - polyvinylpyrrolidone ........... . . . . . . . . . . . . . . . . . . . . . . ..0.0l3 g L crosslinked polyvinylpyrrolidone. . . . . . . . . . . ............. 0.0S g - talk ... . . . . _.... . . . . ................. . . . .............. 0.08 g silica "Aerosil 200" supplied by sté DEGUSSA0.001 g - lactose q.s.p .......................................... 100 g In this example, the 1,8-dihydoxy-10- (2-thienyl) anthrone can be replaced by taken with an equivalent amount of 1,8-dihydroxy-10 (3'-methoxy) -phenyl) -antron.
Exemgel 3 Komgositíon i form av i sirag Vid användníngstíllfället blandar man under omrörning i 60 ml mineralvatten 30 g av ett pulver med följande sammansättning: 10 15 20 25 30 35 459 807 24 1.8-dihydroxí-10-(3'-hyâroxi-fenyl)-antron............0.6 g - natriumbensoat . . . . _..........................0.l5 q - natriumkloríd . . . . . _. ........... . . . . . ..................o.23 g - vattenfrítt natríumcítrat . . . . . . . . . . . ..................l,l g - ammoniumglycyrrhízínat . . . . . . . . . . . . . . . . . . _. ............0.06 g - arom q.s. - fârgämne q.s.Exemgel 3 Komgositíon in the form of i sirag At the time of use, mix with stirring in 60 ml mineral water 30 g of a powder of the following composition: 10 15 20 25 30 35 459 807 24 1,8-Dihydroxy-10- (3'-hydroxy-phenyl) -antrone ............ 0.6 g - sodium benzoate . . . . _.......................... 0.l5 q - sodium chloride. . . . . _. ............ . . . . .................. o.23 g anhydrous sodium citrate. . . . . . . . . . . .................. l, l g - ammonium glycyrrhizinate. . . . . . . . . . . . . . . . . . _. ............ 0.06 g - arom q.s. - dye q.s.
- Sackaros q.s.p . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ......3o g När sírapen en gång erhållits bör den förvaras svalt, varvid dess stabilitet ej överskrider 7 dagar.- Sackaros q.s.p. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ...... 3o g Once obtained, the syrup should be kept cool, whereby its stability does not exceed 7 days.
Exemgel 4 flydrofob vattenfri gel - 1.8-díhydroxi-10-(3'-hydroxí-fenyl)-antron . . . . . . . . . . . . ..l g - kíselsyra “ABROSOL 200” tíllhandahållen av sté DEGUSSA..7 g - ísopropylmyristat q.s.p . . . . . . . . . . . . . . . . _.. . . . . . . . . . . ..l00 g Exemgel 5 fiydrofob, tillslutande salva - 1.8-díhydroxí-10-(2'-metoxí-fenyl)-antron.._..........l.6 g - ceresín........................... . . . . ...............15 g - vaselínolja . . . . . .......... . . . . . . . ....................35 g - vaselín q.s.p.. . . . . . . . . . . . _.. . . . . . . . . . ..... . . . . . ....100 g I detta exempel kan 1,8-díhydroxí-10-(2'-metoxi~fenyl)-antro- nen ersättas med en ekvívalent mängd av 1.8-díhydroxí-10-(3'- -metoxí-fenyl)-antron.Exemgel 4 fl hydrophobic anhydrous gel 1,8-Dihydroxy-10- (3'-hydroxy-phenyl) -anthrone. . . . . . . . . . . . ..l g - silica “ABROSOL 200” supplied by sté DEGUSSA..7 g isopropyl myristate q.s.p. . . . . . . . . . . . . . . . _ ... . . . . . . . . . ..l00 g Example 5 fi hydrophobic, closing ointment 1,8-Dihydroxy-10- (2'-methoxy-phenyl) -anthrone. - ceresín ............................ . . . ............... 15 g - Vaseline oil. . . . . ........... . . . . . . .................... 35 g - Vaseline q.s.p ... . . . . . . . . . . _ ... . . . . . . . . ...... . . . . .... 100 g In this example, 1,8-dihydroxy-10- (2'-methoxy-phenyl) -anthro- is replaced by an equivalent amount of 1,8-dihydroxy-10- (3'- -methoxy-phenyl) -antrone.
Exemgel 6 gygrofob salva í form av pasta - 1,8-díhydroxí-10-(2-tíenyl}-antron._.... . . . . . . . . . . . . ..1.5 g - ísopropylmyrístat . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ..36,4 g - sílíkonolja (dímetylpolysíloxan tíllhandahållen av firman RHONE POULENC under benämningen RHODORSIL 47 V 300 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ..36.4 g 5 10 15 20 25 30 35 25 459 807 - bivax........ . . . . .............. . . . . . . . . . . . . . ... . . . . ..l3.6 g - sílikonolja tillhandahållen av sté GOLDSCHMIDT under benämningen "ABIL 300 000 est” q.s.p . . . . . . . . . . ......l00 g Exemgel 7 En dos shamponeríngsmedel i två delar att blanda vid tillfället l) Behandlande del í form av suspension - 1.8-díhydroxí-10~(3'~metoxi-fenyl)-antron . . . . . . . . . . . ..0.S g - vaselínolja q.s.p..... . . . . ... . . . . . . . . . . . . . . . . . . . . . ..100 g 2) Tvättande del - dodekandíolpolyglycerolerad med 3,5 moler . . . . . . . .....20 g - förening med följande forme1:.........................1.75 g HO-(?H-CH2O)x--(CH2-CHZO)n--(CH2-EH)y-H R R = C H NJ 14 29 3 001111-70 .X-O-Y= - vatten q.s.p . . . . . . . . . . . .... . . . . . . . . . . . . . . ...........100 g Den behandlande delen blandas. sedan den rörts on kraftigt, i en flaska för applícering med den tvättanderdelen i ett för- hållande 10/90. När blandningen en gång erhållits bör den an- vändas omedelbart.Example 6 gygrophobic ointment in the form of pasta - 1,8-Dihydroxy-10- (2-thienyl} -antrone ._............... .1.5 g isopropyl myristate. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ..36.4 g silicone oil (dimethylpolysiloxane supplied by the company RHONE POULENC under the name RHODORSIL 47 V 300. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ..36.4 g 5 10 15 20 25 30 35 25 459 807 - bivax ......... . . . ............... . . . . . . . . . . . . .... . . . ..l3.6 g silicone oil provided by sté GOLDSCHMIDT under the name "ABIL 300 000 est" q.s.p........ ...... l00 g Example 7 A dose of shampoo in two parts to mix at the moment l) Treating part in the form of suspension 1,8-Dihydroxy-10 - (3 '- methoxy-phenyl) -antrone. . . . . . . . . . . ..0.S g - Vaseline oil q.s.p ...... . . . .... . . . . . . . . . . . . . . . . . . . . ..100 g 2) Washing part dodecanediol polyglycerolated with 3.5 moles. . . . . . . ..... 20 g compound of the following form1: ......................... 1.75 g HO - (? H-CH 2 O) x - (CH 2 -CH 2 O) n - (CH 2 -EH) y -H R R = C H NJ 14 29 3 001111-70 .X-O-Y = - water q.s.p. . . . . . . . . . . ..... . . . . . . . . . . . . . ........... 100 g The treating part is mixed. after it has been stirred vigorously, i a bottle for application with that detergent portion in a pre- holding 10/90. Once the mixture is obtained, it should be turned immediately.
Exemgel 8 Anti-acne-komposition í form av en kräm _ magnesíumlanolat . . . . . . . . . . . . . . . . . . . . . . ... . . . . . . .......3.4 g - lanolínalkohol... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ......2,8 g - perhydroskvalen . . . . . . . . . . . . . . . . . . . . . . . . . . ... . . . . . . . ._20 g - isopropylmyristat . . . . .._..............................5 g - obearbetad sesamolja . . . . . .... . . . . . ......,............10 g - vaselínolja. . . . . . .f . . . . . . . . . . . . . . . . . . . . . . . . ... . . . . . . ..8.8 g _ salícy1syra...........................................l g - 10-(2-tienyl)-1.8.9-trípropanoyloxi-antracen..........l g _ metyl-parahydroxibensoat . . . . . . . . . . . . . . . . . . . . . . . . . . . . ..0.3 g - vatten q.s.p . . . . . . . . . . ....,........;................100 g 10 15 20 25 459 807 26 Exemgel 9 Hårkomgosítíon mot håravfall och mot mjäll - 10-(3'-metoxí-fenyl)-1.8.9-tríacetoxí-antracen . . . . . . ..0.S 9 - salícylsyra . . . . . . . ........ . . . . . . . . . . . . . . . . . . _.. . . . . ...0.1 g - bensylsalicylat . . . . . ..... . . . . . . . . . . . . . . . . . . . . . . . . . ..100 g Bxemgel 10 Hårkomgosítion mot håravfall och mot mjäll - 1,8-dípívaloyloxí-10-(2'-tíenyl)-antron . . . . . . . . . . . . . ..0,8 g - tenn(II)k1orid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ..0,3 g - ísopropylmyrístat q.s.p...... . . . . . . . . . . . . . . . . . . . . . ..100 g Exemgel 11 Lotíons mot seborré En lösning bestående av 10 cm3 etanol 950 3 och 30 cm polyetylenglykol (PSG) 400 innehållande 30 mg butylhydroxito- luen försâttes med 0.2 g 1.8 -dipívaloyloxí-10-(2'-tíeny1)- -antron.Exemgel 8 Anti-acne composition in the form of a cream _ magnesium lanolate. . . . . . . . . . . . . . . . . . . . . . .... . . . . . ....... 3.4 g - lanolin alcohol .... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ...... 2.8 g perhydrosvalence. . . . . . . . . . . . . . . . . . . . . . . . . . .... . . . . . . ._20 g isopropyl myristate. . . . .._.............................. 5 g - unprocessed sesame oil. . . . . ..... . . . . ......, ............ 10 g - Vaseline oil. . . . . . .f. . . . . . . . . . . . . . . . . . . . . . . . .... . . . . . ..8.8 g _ salicylic acid ........................................... l g - 10- (2-thienyl) -1.8.9-tripropanoyloxy-anthracene .......... 1 g methyl parahydroxybenzoate. . . . . . . . . . . . . . . . . . . . . . . . . . . . ..0.3 g - water q.s.p. . . . . . . . . . ...., ........; ................ 100 g 10 15 20 25 459 807 26 Example 9 Hair combination against hair loss and against dandruff 10- (3'-methoxy-phenyl) -1.8.9-triacetoxy-anthracene. . . . . . ..0.S 9 - salicylic acid. . . . . . . ......... . . . . . . . . . . . . . . . . . _ ... . . . ... 0.1 g benzyl salicylate. . . . . ...... . . . . . . . . . . . . . . . . . . . . . . . . ..100 g Bxemgel 10 Hair combination against hair loss and against dandruff 1,8-Dipivalovyloxy-10- (2'-thienyl) -antrone. . . . . . . . . . . . . ..0.8 g - tin (II) chloride. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ..0.3 g - isopropyl myristate q.s.p ....... . . . . . . . . . . . . . . . . . . . . ..100 g Example 11 Lotions with seborrhea A solution consisting of 10 cm3 of ethanol 950 3 and 30 cm polyethylene glycol (PSG) 400 containing 30 mg of butyl hydroxy the cap was added with 0.2 g 1.8 -dipivalovyloxy-10- (2'-thienyl) - -antron.
Efter solubílíseríng under omrörning anbríngar man lotion på hela hârmanen.After solubilization while stirring, apply lotion the whole man.
Förecrädesvís bör denna behandling utföras två gånger per dag.Preferably, this treatment should be performed twice a day.
Claims (14)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR8409203A FR2565966B1 (en) | 1984-06-13 | 1984-06-13 | ARYL-10 DIHYDROXY-1,8 ANTHRONES AND THEIR ESTERS, THEIR PREPARATION PROCESS AND THEIR USE IN HUMAN OR VETERINARY MEDICINE AND IN COSMETICS |
Publications (3)
Publication Number | Publication Date |
---|---|
SE8502910D0 SE8502910D0 (en) | 1985-06-12 |
SE8502910L SE8502910L (en) | 1985-12-14 |
SE459807B true SE459807B (en) | 1989-08-07 |
Family
ID=9304944
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE8502910A SE459807B (en) | 1984-06-13 | 1985-06-12 | 10-ARYL-1, 8-DIHYDROXY ANTRONES, PROCEDURES FOR PREPARING THEREOF AND PHARMACEUTICAL OR COSMETIC COMPOSITIONS |
Country Status (11)
Country | Link |
---|---|
JP (1) | JPS6140238A (en) |
BE (1) | BE902642A (en) |
CA (1) | CA1253859A (en) |
CH (1) | CH664557A5 (en) |
DE (1) | DE3521074A1 (en) |
DK (1) | DK265185A (en) |
FR (1) | FR2565966B1 (en) |
GB (1) | GB2160864B (en) |
IT (1) | IT1190365B (en) |
NL (1) | NL8501699A (en) |
SE (1) | SE459807B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4843097A (en) * | 1984-06-13 | 1989-06-27 | Groupement D'interet Economique Dit: Centre International De Recherches Dermatologiques C.I.R.D. | 10-aryl-1,8-dihydroxy-9-anthrones and their esters, process for preparing same, and use of same in human and veterinary medicine and in cosmetics |
DE4231636A1 (en) * | 1992-09-22 | 1994-03-24 | Beiersdorf Ag | New anthrone and anthracene derivatives substituted in the 10-position, processes for their preparation, pharmaceutical or cosmetic compositions containing these compounds and their use |
US5426197A (en) * | 1993-07-19 | 1995-06-20 | Teva Pharmaceutical Industries, Ltd. | 10-substituted 1,8-dihydroxy-9(10H) anthracenone pharmaceuticals |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL31289A (en) * | 1968-01-08 | 1974-01-14 | Ciba Geigy Ag | Pharmaceutical preparation containing a dermatologically active difluorinated corticoid and dithranol |
DE2154608A1 (en) * | 1970-11-12 | 1972-06-29 | Ciba-Geigy Ag, Basel (Schweiz) | New diacetate, pharmaceutical preparations and manufacturing processes |
DE3002089A1 (en) * | 1980-01-22 | 1981-07-23 | Dr. Karl Thomae Gmbh, 7950 Biberach | NEW, SUBSTITUTED 1,8-DIHYDROXY-9- (10H) -ANTHRACENONE, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS |
FR2492372A1 (en) * | 1980-10-21 | 1982-04-23 | Cird | 1,8-DIHYDROXY-9-ANTHRONES SUBSTITUTED IN POSITION 10 AND THEIR USE IN HUMAN OR VETERINARY MEDICINE AND IN COSMETICS |
FR2495934A1 (en) * | 1980-12-15 | 1982-06-18 | Cird | COMPOSITION FOR THE TREATMENT OF PSORIASIS BASED ON SUBSTITUTED-1,8-DIHYDROXY-1,8-ANTHRONE-9 |
-
1984
- 1984-06-13 FR FR8409203A patent/FR2565966B1/en not_active Expired
-
1985
- 1985-06-12 IT IT21130/85A patent/IT1190365B/en active
- 1985-06-12 SE SE8502910A patent/SE459807B/en not_active IP Right Cessation
- 1985-06-12 NL NL8501699A patent/NL8501699A/en not_active Application Discontinuation
- 1985-06-12 CA CA000483819A patent/CA1253859A/en not_active Expired
- 1985-06-12 CH CH2510/85A patent/CH664557A5/en not_active IP Right Cessation
- 1985-06-12 DE DE19853521074 patent/DE3521074A1/en not_active Withdrawn
- 1985-06-12 BE BE0/215174A patent/BE902642A/en not_active IP Right Cessation
- 1985-06-12 DK DK265185A patent/DK265185A/en unknown
- 1985-06-12 JP JP12639185A patent/JPS6140238A/en active Pending
- 1985-06-13 GB GB08514973A patent/GB2160864B/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
DK265185A (en) | 1985-12-14 |
CH664557A5 (en) | 1988-03-15 |
IT1190365B (en) | 1988-02-16 |
BE902642A (en) | 1985-12-12 |
GB2160864B (en) | 1987-12-31 |
SE8502910L (en) | 1985-12-14 |
SE8502910D0 (en) | 1985-06-12 |
GB2160864A (en) | 1986-01-02 |
FR2565966B1 (en) | 1986-08-29 |
CA1253859A (en) | 1989-05-09 |
IT8521130A0 (en) | 1985-06-12 |
FR2565966A1 (en) | 1985-12-20 |
DE3521074A1 (en) | 1985-12-19 |
DK265185D0 (en) | 1985-06-12 |
NL8501699A (en) | 1986-01-02 |
JPS6140238A (en) | 1986-02-26 |
GB8514973D0 (en) | 1985-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK172070B1 (en) | Benzonaphthalene derivatives, processes for their preparation and use, and their pharmaceutical and cosmetic preparations | |
DE3443231C2 (en) | Polysubstituted naphthalene derivatives, process for their preparation and pharmaceutical and cosmetic preparations containing these compounds | |
JPS62502471A (en) | A novel naphthalene derivative with retinoid-type action, its production method, and pharmaceutical and cosmetic compositions containing the same | |
JPS62234078A (en) | Benzopyranyl and benzothiopyranylbenzene compounds, their production methods, cosmetics, and human and animal drugs | |
JP2705792B2 (en) | Bicyclic aromatic compound, process for producing the same, and composition for treating skin and scalp containing the same | |
JPH04257587A (en) | Codeine salts of substituted carboxylic acids | |
DE3711546A1 (en) | AROMATIC COMPOUNDS, METHOD FOR THEIR PRODUCTION AND THEIR USE IN HUMAN AND VETERINE MEDICINE AND IN COSMETICS | |
JPS62221681A (en) | Novel benzofuran derivatives, methods for producing the same, and pharmaceutical and cosmetic compositions containing the same | |
EP0051077A1 (en) | Substituted oxocarboxylic acids, process for their preparation, their use and medicines containing them | |
SE459807B (en) | 10-ARYL-1, 8-DIHYDROXY ANTRONES, PROCEDURES FOR PREPARING THEREOF AND PHARMACEUTICAL OR COSMETIC COMPOSITIONS | |
US4843097A (en) | 10-aryl-1,8-dihydroxy-9-anthrones and their esters, process for preparing same, and use of same in human and veterinary medicine and in cosmetics | |
WO2000051602A1 (en) | Utilization of polycyclic 2-amino-thiazole systems in the production of medicaments for prophylaxis or treatment of obesity | |
SE500215C2 (en) | New aromatic naphthyl compounds, their preparation and their use in human and veterinary medicine and in cosmetics | |
US4696941A (en) | 1,8-diacyloxy-10-acylanthrones | |
SE442300B (en) | 6,7-DIHYDRO-8H-PYRANO / 3,2-G / CHROMON-2-CARBOXYLIC ACID DERIVATIVES AND THEIR USE IN ANTIALLERGICALLY EFFECTIVE THERAPEUTIC COMPOSITIONS | |
US5061713A (en) | Analgesic oxazolopyridine compounds | |
TW418186B (en) | Retinoid-like compounds | |
DK170399B1 (en) | Naphthalene derivatives of the benzonorborn, process for their preparation and pharmaceuticals and cosmetics containing such compounds | |
JPH02124A (en) | Novel norbornene derivatives, methods for their production, cosmetic and pharmaceutical compositions containing them | |
JPS62187431A (en) | Mono-, di- and tri-ester of 1,8-dihydroxy-10-phenyl-9-anthrone or 9-anthranol, manufacture and medicinal and cosmetic composition | |
JPH03145484A (en) | Substituted dibenzofurans and their usage | |
CN105143162B (en) | Method of synthesis | |
JPH0827057A (en) | Novel substance having antioxidant action and method for producing the same | |
EP0495917A1 (en) | Lipoxygenase inhibitors | |
KR0171692B1 (en) | Chromone derivative and manufacturing method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NUG | Patent has lapsed |
Ref document number: 8502910-6 Effective date: 19940110 Format of ref document f/p: F |